Microsoft word - philip cv 2-28-2007.doc

PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P.
Baccalaureate, American Jesuit Fathers’ College, Baghdad, Iraq. M.D. Degree, University of Baghdad, College of Medicine, Baghdad, Iraq. Ph.D. in Clinical Pharmacology and Pharmacogenetics, University of London, Guy’s Hospital Medical School, London, UK. Intern in Internal Medicine and General Surgery, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq. Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq. Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq. Lecturer in Clinical Pharmacology, Baghdad University Medical College, Baghdad, Iraq. Resident Medical Officer, St. Raphael Hospital, Baghdad, Iraq. Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology and the Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom. Registrar in Medical Oncology, Charing Cross Hospital, University of London, London, United Kingdom. Registrar in Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, University of Manchester, United Kingdom. Senior Registrar in Medical Oncology, University of Oxford and Imperial Cancer Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, United Kingdom. Fellow in Medical Oncology, MD Anderson Cancer Center, Houston, Texas. Philip Agop Philip Curriculum Vitae Page Two Faculty Appointments 1995 -1998 Assistant Professor (Clinician-Educator Track), Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Associate Professor (Clinician-Educator Track) in Medicine, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Associate Professor in Oncology, Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center Detroit, MI Professor (Clinician-Educator Track) in Medicine, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Clinical Professor in Oncology, Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center, Detroit, MI Director of Gastrointestinal Oncology, Karmanos Cancer Institute Chair, Protocol Review and Monitoring Committee. Hospital or Other Professional Appointments 1995 - Present Attending Physician in Hematology/Oncology at the Detroit Medical Center (DMC), Detroit, MI. Privileges at the Harper University Hospital, the Detroit Receiving Hospital and at the Hutzel Hospital. Attending Physician at Karmanos Cancer Hospital Member, ASCO Educational Committee, Non-Colorectal GI School of Medicine Committee to review the Department of Surgery Member of the Scientific Leadership Council, Karmanos Cancer Institute Leader of Pancreas and Liver Cancer Subcommittee and member of the Steering Committee for GI Cancer, Southwest Oncology Group (SWOG) Member of the USA Task Force on Pancreatic Cancer Member, MD/PhD admission committee, School of Medicine, Wayne State University Member, Financial Conflict of Interest Committee, Wayne Sate University Member, Clinical Leadership Council, Karmanos Cancer Institute Member, Primary Cancer Prevention Task Force, Karmanos Cancer Institute Human Applications Group, Institute of Chemical Toxicology, Wayne State University Member, CTEP site visit to New York University, Cancer Center Member in the Protocol Review Committee, Karmanos Cancer Institute Philip Agop Philip Curriculum Vitae Page Three 1997 - present Member, Drug Development Program, Karmanos Cancer Institute Member, Wertz Business/Clinical Audit Committee, Karmanos Cancer Institute Wertz Clinical Care Center Operational Focus Group, Karmanos Cancer Institute Member, Fellows Education Committee, Oncology Fellowship Oncology Program, WSU Member, DMC Hematology/Oncology Pharmacy Therapeutics Subcommittee Philip Agop Philip Curriculum Vitae Page Three SERVICE Patient Care Medical Oncology – Karmanos Cancer Hospital, Harper University Hospital, Detroit Receiving Hospital, and Hutzel Hospital Medical Oncology - Karmanos Cancer Hospital, Harper University Hospital, Detroit Receiving Hospital, and Hutzel Hospital GI Multidisciplinary Program - one clinic per week (Monday PM) GI Medical Oncology - one clinic per week (Monday AM) Weisberg Center Clinic- one clinic per week (Tuesday PM) GI Medical Oncology - one clinic per week (Thursday all day) Major Professional Societies • Pharmacology and Molecular Mechanisms Group (PAMM) of the European Organization for Research and Treatment of Cancer (EORTC) (1990 - present) • American Association for Cancer Research (AACR)(1995 - present) • American Society of Clinical Oncology (ASCO)(1995 - present) • Society of Toxicology, Michigan Regional Chapter (1996 - 2004) • American Society of Clinical Pharmacology and Therapeutics (ASCPT) 1998- 2004) • Southwest Oncology Group (SWOG) (1995 - present) • American College of Physicians (ACP) (1998 - 2000) • NSABP (1998 - 2000) • American Pancreatic Association (APA) (2000-present) Board Certifications • ABIM certification in Internal Medicine • ABIM certification in Medical Oncology • M.R.C.P. (Internal Medicine Diploma), Royal College of Physicians of the United Kingdom • Accreditation in the Subspecialty of Medical Oncology by the Joint Committee for Higher Medical Training of the United Kingdom and the Royal College of Physicians of the UK • Fellowship of the Royal College of Physicians (FRCP) of the UK Licensures • Michigan State Medical License, #4301066240 • Kansas State Medical License (inactive), #04-25728 • General Medical Counsel of the United Kingdom (UK Licensure), #3386011 Philip Agop Philip Curriculum Vitae Page Four Honors and Awards • Fifth graduate in the Country for the National Baccalaureate Exam, 1971 • First in the Pharmacology and Therapeutics Course, Medical School, 1974 • Fourth in Internal Medicine course, Medical School, 1977 • Ninth graduate in class of 300 from Medical School, 1977 • Scholarship from the University of Baghdad – Clinical Pharmacology/Medical Oncology, 1982-86 • Fellows Competition Award, M.D. Anderson Cancer Center, 1994 • Wayne State University Medical School Teaching Award, 1999 • Outstanding Instructor in Oncology Award, Wayne State University, Oncology Fellowship Program • Wayne State University Medical School Teaching Award, 2004

COMMUNITY OUTREACH:
1988-1992
Secretary, Armenian Medical Association of Great Britain Seminar, Breast Cancer in the New Millennium, “Clinical Pathways for Advanced Stage Breast Cancer Channel 4 TV News, “Colo-Rectal Cancer” Channel 4 TV News, “Angiostatin, Endostatin” Channel 4 TV News, “Questions from the Public” WOMC Radio Station, “New Drugs in Cancer” Channel 50, “Ethnicity and Outcome of Breast Cancer” Channel 4 TV News, "Colo-rectal Cancer Week" Live interview on WWJ 950 on the sale of anti-cancer drugs on the Internet Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute Channel 4 News, “Questions from the Public” on Colorectal Cancer Channel 4 News, “New anticancer drug” Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute Comcast TV interview on Breast Cancer with Frankie Dorcell “Flashpoint” Sunday Program, Channel 4 TV, interview on Colorectal Cancer Screening Interview with “Daily Macomb” Newspaper on colorectal cancer screening WHMI/FM interview on new treatments for colo-rectal cancer TV Channel 2, “Oral Chemotherapy for Colorectal Cancer” Radio WJR “diagnosis of breast cancer” Magazine interview with Metro Parent on new drugs and trials in breast cancer Lecture on Cancer Prevention, Association of Armenians from Istanbul Presentation and media interviews, Colossal Colon Tour opening ceremony, Detroit Chaldean Radio live interview on colorectal cancer WPGR, Live radio program with Dr Jimmy Womack on colorectal cancer Radio show interview, "Senior Solutions" on colorectal cancer Lecture at the Gilda’s Club in Royal Oak to patients and relatives Question and answer session with 5th grade students at the AGBU Alex Manougian School in Southfield, MI Radio interview with WWJ on a recent article on Aspirin and risk of breast cancer TV Channel 4 News, interview on the results of reduction of incidence of breast Fundraising for KCI at Panera Bread Dearborn – Michael Guido Pancreas TV Channel 4 News live phone bank on colorectal cancer Philip Agop Philip Curriculum Vitae Page Five JOURNAL EDITORIAL ACTIVITY Associate Editor: Gastrointestinal Cancer Member of Editorial Board: The Internet Journal of Oncology (ISSN 1528-8331) Community Oncology Ad hoc reviewer for: Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer, Pancreas, Drug Metabolism and Disposition, Cancer, Journal of Clinical Outcomes Management, Cancer Research, International Journal of Cancer, Clinical Cancer Research, Expert Opinion on Pharmacotherapy, Cancer Investigation, The Oncologist, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Future Medicine, Gut Editorial Consultant for: Physician’s Information and Education Resource (PIER), Pancreatic Cancer Module (2003-2006) TEACHING ACTIVITIES AT WAYNE STATE UNIVERSITY (1995-present) Graduate Students (Cancer Biology Program): Ph.D. Student rotation in clinic (8/96, 8/97, 6/99, 8/99, 6/2001, 7/2001, 6/2003, 7/2003, 6/05, 7/05, 8/05, 6/06) Lecturer Cancer Biology Program (CB725) Cancer Prevention and Control Course (2/98, 2/99) “Role of Carcinogen-Metabolizing Enzymes in Cancer Susceptibility” Lecturer, CB7210 Fundamentals of Cancer Biology Course “Clinical issues: detection, diagnosis and treatment” (1/16/03) “Clinical issues: detection, diagnosis and treatment” (1/27/04) “Clinical issues: detection, diagnosis and treatment” (1/20/05) “Clinical issues: detection, diagnosis and treatment” (1/20/06) “Clinical issues: detection, diagnosis and treatment” (1/20/07) Physical Diagnosis for sophomore medical students (2/1/96-4/25/96; 2/97-4/97) Pharmacology course for second year medical students (9/96) Hematology/Oncology Clinic Rotation (2/97, 4/99, 9/01, 1/02, 2/02) OSCE Proctor for IIIY Medical Students (6/98, 6/99) USMLE Step II Course (8/98) Internal Medicine Teaching Rounds (6/98, 1/99) Physical diagnosis mid-term examiner (2/2000) Oncology Elective, Ms Sevan Karadolian, October, 2005 Philip Agop Philip Curriculum Vitae Page Six WSU Internal Medicine Residency Training Program: Internal Medicine Rounds at Detroit Receiving Hospital - (12/95) Morning Report at Detroit Receiving Hospital (12/95) Medical Oncology Teaching Rounds - Harper Hospital - (10/96, 10/99, 10/00, 9/01, 1/02) Morning Report at Harper Hospital (10/96) - attendee Internal Medicine Rounds at Harper Hospital (6/98) Morning Report at Harper Hospital (6/98) Internal Medicine Rounds at Harper Hospital (1/99) Morning Report (1/99) Division of Hematology and Oncology, Core Oncology Lecture Series, Bi-monthly (1995-1998) Internal Medicine Board Review Course: "Gastrointestinal Malignancies," 4/6/1999, 10/99 Visiting Professor, Grace-Sinai Hospital, 12/00 & 5/01 Outpatient Oncology Teaching, two sessions per week, (1999- present) Medical Specialty Teaching Rounds, Harper Hospital, 12/14 – 12/29/03 Medical Specialty Teaching Rounds, Harper Hospital, 12/14 – 12/29/04 Medical Specialty Teaching Rounds, Harper Hospital, 5/13 – 5/29/05 Medical Specialty Teaching Rounds, Karmanos Cancer Hospital, 2/14 – 2/28/06 Medical Specialty Teaching Rounds, Karmanos Cancer Hospital, 8/14 – 8/24/06 WSU Oncology Fellowship Training Program: Fellow’s Clinic, 1 month/year (March 1996, January 97) GI Multidisciplinary Clinic 10 months/year Breast Clinic, 6 months/year (1995 – 2002) Fellow’s Core lecture Series (1/01, 6/01) WSU Radiation Oncology Residency Training Program: Lectures, March 1996, June 1998, June 1999 Hematology/Oncology Clinic Rotation (8/96, 3/97-9/97, 7/98) 2 Lectures, August 1996, 1 Lecture, October 1997 1 Lecture, December 1998, 1 Lecture Dec 1999 2 Lectures, December 2001 2 Lectures, December 2002 2 Lectures, December 2003 1 Lecture, December 2004 Clinic Rotations: 10/97, 3/98, 2/99, 10/99, 2/2000 (one month in outpatient clinic + inpatients), 9-12/02, 1/03 Philip Agop Philip Curriculum Vitae Page Seven Activity Director, monthly, 2000- present Course Director, Sept 2001, Sept 2002, Sept 2003 Course Cancer” “Supportive Care Symposium” Course Director, November 2003, November “Karmanos Cancer Institute’s Grand Rounds” Co-Director of the weekly activity, Sept 2003- Present
“GI Tumor Board”
TEACHING ACTIVITIES AT OTHER UNIVERSITIES (1980-1993) 1980-1982 University of Baghdad, College of Medicine, Pharmacology courses for medical University of London, Guy’s Hospital Medical School, Clinical Pharmacology courses for medical students University of London, Charing Cross Hospital, Residency Training Program in Internal Medicine University of Oxford, School of Medicine, Residency Training Program in Internal Medicine; Fellowship Training Program in Medical Oncology Philip Agop Philip Curriculum Vitae Page Eight MENTORSHIP: Medical Oncology Fellowship Program (Dr. Shirish Gadgeel), 7/1996-9/2000 Laboratory Research, Visiting Scholar, (Dr. A. Akhtar), 1996 – 1997 Summer Wayne State University College Student, (Mr. Mohamed Rehman), 6/1/97-8/1/97 Summer High-School Student (in lab) (Anuj Prasher), 6/22/98-8/22/98 Summer College Student (in lab) (Brian Scallen), 5/99-7/99 Internal Medicine Resident (Elective in the laboratory), Dr. Kambeez Berenji, (8/30/99-10/31/99) Medical Oncology Fellowship Program, (Dr. Basil El-Rayes), 7/2000-2004 Internal Medicine Residency Intern, Dr. Nirav, 2002 Internal Medicine Intern, Dr. Pallavi Jasti, 2003-2004 Internal Medicine second year resident, Dr. Vera Maranci, 2005 – present Internal Medicine second year resident, Dr. C. Deol, 2005 – 2006 Internal Medicine second year resident, Dr M Mobayed, 2006 - Philip Agop Philip Curriculum Vitae Grants Page One GRANT SUPPORT: NCI-2U10 CA 14028-24, (total = $218,354). Southwest Oncology Group. P.I., L.E. Flaherty, Philip Agop Philip, 5% effort. January 1, 1978 through December 31, 1998. NIH – ROI CA61526-02, (total = $91,304). “New Drug Combinations for Breast Cancer.” P.I., P. M. LoRusso, Philip Agop Philip, 5% effort. August 1, 1993 through May 31, 1998. National Institutes of Health/National Institute of Environmental Health Sciences, (total = $10,000). “A study of differences in the expression of xenobiotic metabolizing enzymes in the oral mucosa of African-Americans and Caucasians.” P.I., Philip Agop Philip. April 1, 1995 through March 31, 1997. Sequus Pharmaceuticals, Inc., (total = $5,000). “Doxil and paclitaxel AIDS-related Kaposi’s sarcoma.” P.I., Philip Agop Philip. June 1996. Harper Hospital Medical Staff Trust Fund Role, (direct cost = $19,400/indirect cost = 0/closed), Funded July 1, 1996 through April 30, 1997. “Role of cytochrome P-450 3A4 enzyme in the pharmacokinetics of cyclophosphamide and cytotoxic metabolite formation in patients with cancer.” P.I., Philip Agop Philip. July 1, 1996 through April 30, 1997. Sequus Pharmaceuticals, Inc., (total = $5,000). “Doxil and Cyclophosphamide/Phase I Study.” P.I., Philip Agop Philip. October 1996. Eli-Lilly, (total = $66,000). “Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced Pancreatic Cancer.” P.I., Philip Agop Philip. December 1, 1996 through November 30, 1998. Rhone-Poulenc Rorer Pharmaceuticals, Inc., (direct cost = $100,501, indirect costs = $18,091, total = $118,592). “A Phase II Study of the Combination of Taxotere, Doxorubicin and Infusional 5-FU in the Treatment of Locally Advanced Breast Cancer.” P.I., Philip Agop Philip. January 1, 1997 through December 31, 2000. Bristol-Myers Squibb, (total = $120,000). “Carboplatin and paclitaxel in esophageal, gastric and unknown primary cancers.” P.I., Philip Agop Philip. January 1997. Lilly Research Laboratories Protocol #B9E-MC-X027, (direct cost = $55,085, indirect cost = $9,915, total = $65,000). “A Study of Gemcitabine and Cisplatin in The Treatment of Advanced or Metastatic Pancreatic Cancer.” April 1, 1997 through August 31, 2001. Affiliated Internists, (total = $24,000). “A Study of the Influence of Cellular Expression of Carcinogen-Metabolizing Enzymes on the Presence of Mutated p53 in Peri-tumoral Mucosal Cells in Patients with Head and Neck Cancer.” P.I., Philip Agop Philip. June 1997. Philip Agop Philip Curriculum Vitae Grants Page Two 12. Eli-Lilly (total = $75,000). “Phase II Study of Gemcitabine in Patients with Breast Cancer Who Relapse After High-Dose Chemotherapy and Autologous Bone Marrow Transplant.” P.I., Philip Agop Philip. September 1, 1997 through November 30, 1998. Eli-Lilly, (total = $75,000). “Phase II Study of Gemzar and Doxil in Patients with Liposomal Doxorubicin in Advanced Breast Cancer.” P.I., Philip Agop Philip. September 15, 1997 through September 14, 1998. Lilly Research Laboratories #B9E-MC-X097, (direct cost = $20,212, indirect cost = $3,638, total = $23,850). “Study of Gemcitabine and Liposomal Doxorubicin (Doxil) in Patients with Advanced Breast Cancer.” P.I., Philip Agop Philip. September 15, 1997 through December 31, 2001. Eli-Lilly PO #4500007890/#B9E-MC-X103, (direct cost = $10,169, indirect cost = $1,831, total = $12,000). “Study of Gemcitabine in Patients with Advanced Breast Cancer who Relapsed After High-Dose Chemotherapy and Autologous Bone Marrow Transplantation.” December 1, 1997 through December 31, 2002. NCI, 2U10 CA 14028-25, (total = $227,088). “Southwest Oncology Group.” P.I., L.E. Flaherty, Philip Agop Philip, 5% effort. January 1, 1998 through December 31, 2002. Eli Lilly PO#4500007955/#B9E-MC-X148 (direct cost = $43,433, indirect cost = $7,817, total = $51,250). “Phase I Study of Gemzar and UFT/Leucovorin in Solid Tumors.” March 1, 1998 Karmanos Cancer Institute, Virtual Discovery Grant, (total = $75,000). “Evaluation of the Mechanisms and Magnitude of Radiation-Induced Cardiac Toxicity in Left-Sided Breast Cancer Patients.” Co-investigator, Philip Agop Philip, 20% effort. April 1, 1998 through August 31, 1999. Bristol-Myers Squibb (direct cost = $33,898, indirect cost = $6,102, total = $40,000). “Phase I Study of Gemcitabine (GEMZAR) and UFT/Leucovorin.” P.I., Philip Agop Philip. September 1, 1998 through December 31, 2002. Department of Defense (total = $314,989). “Role of RAD6, a DNA Repair Gene, in Tumor Progression and Drug Resistance.” P.I. Malathy Shekhar Ph.D., Philip Agop Philip. 5% effort, May 1, 1999 through April 30, 2002. Bristol-Myers-Squibb (total = $5,000). “Correlation Studies in Advanced Stomach/Esophageal Cancers.” P.I. Philip Agop Philip, October 1, 1997 through July 31, 1998. Zeneca Pharmaceuticals #9238IL/0025 (direct cost = $4,237, indirect cost = $763, total = $5,000). “A Double-Blind, Randomized Multicenter Trial Comparing the Efficacy and Tolerability of 250 mg of FASLODEX (Long-Acting ICI 182,780) with 250 mg of NOLVADEX (Tamoxifen) in Postmenopausal Women with Advanced Breast Cancer.” P.I. Philip Agop Philip. February 1, 1999 through December 31, 1999. Philip A. Philip Curriculum Vitae Grants Page Three 23. Zeneca (total = $4,400), “A Double-Blind, Randomized Multicenter Trial Comparing T.” P.I. Philip Agop Philip. June 1, 1999 through August 20, 1999. Lilly Research Laboratories Protocol #B9E-MC-X251 (direct cost = $81,779, indirect cost = $14,721, total = $125,000). “Study of Gemzar, Cisplatin and 5-Fluororacil in the Treatment of Advanced Pancreatic Cancer.” P.I. Philip Agop Philip. September 1, 1999 through August 31, 2002. NIH ($1,250,350). “Labeled Thymidine: Development as a PET Imaging Agent.” P.I. Anthony F. Shields. Philip Agop Philip (Consultant). April 1, 2000 through March 31, 2004. Genentech $ Bristol-Myers Squibb (total = $160,000). “Phase II Study of Herceptin and taxol in Esophageal or Gastro-esophageal Junction Cancers.” P.I. Philip Agop Philip, Pending. May 14, 2000 through January 31, 2002. Tularik, Inc. #T-2004, (direct cost = $13,030, indirect cost = $2,345, total = $75,000). “A Phase I/II Open-Label Study of T138067 – Sodium in Patients with Advanced, Surgically Unrespectable Hepatocellular Carcinoma.” P.I. Philip Agop Philip. October 25, 2000 through September 30, 2002. Sanofi-Synthelabo Research #EFC 4584 Z-2320 (direct cost = $48,729, indirect cost = $8,771, total = $120,000). “Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT- 11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma – EFC-4585.” P.I. Philip Agop Philip. March 1, 2001 through May 31, 2003. 29. Sanofi-Synthelabo Research #EFC-4585 (direct cost = $1,271, indirect cost = $229, total = $120,000). “Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma – EFC-4585.” P.I. Philip Agop Philip. May 4, 2001 through May 31, 2003. Aventis Pharmaceuticals (total = $348,000). “Phase II Study of Neoadjuvant Docetaxel and Vinorelbine with or without Trastuzumab in Patients with Operable Stage I-IIIB Breast Cancer.” P.I. Philip Agop Philip. November 1, 2001 through March 31, 2003. Pfizer, #440E-ONC-0020-348 (direct cost = $21,356, indirect cost = $3,844, total = $184,800). “A Phase II Study of Capecitabine, Celecoxib, and Irinotecan in Patients with Metastatic Colorectal Cancer.” P.I. Philip Agop Philip. January 4, 2002 through October 31, 2004. 32. NIH, ($339,750), “Phase II Study of Genestein, Gemcitabine and Cisplatin in Patents with Advanced Pancreatic Cancer.” P.I. Philip Agop Philip, pending. Philip A. Philip, M.D. Curriculum Vitae Grants Page Four 33. Lilly Research Laboratories Protocol #B9E-MC-S247 (direct cost = $6,520, indirect cost = $1,598, total = $26,868). “A Phase II Trial of Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Resectable or Unresectable Non-Metastatic Pancreatic Cancer.” P.I. Philip Agop Philip. March 1, 2002 through February 28, 2003. Eli Lilly #B93-US-X347, (direct cost = $6,814, indirect cost = $956, total = $84,000). “A Phase II Study of Gemcitabine, Celecoxib, and Cisplatin in Patients with Metastatic Pancreas Cancer .” P.I. Philip A Philip. March 28, 2002 through March 31, 2004. Pfizer and Roche, #440E-ONC-0020-348, $190,300, “A Phase II Study of Capecitabine, Celecoxib, and Irinotecan in Patients with Metastatic Colorectal Cancer.” P.I. Philip Agop Philip, 5% effort. 1/4/02 – 12/31/06. Detroit Medical Center Institute for Oncology and Allied Diseases ($15,000), “Combined Targeting of Cyclooxygenase-2 and NF-κB Pathways in Pancreas Cancer.” P.I. Philip A. Philip, 1/1/03-12/31/03. Lilly, $115,516, “A Phase II Trial of Gemcitabine and Genistein In Metastatic Breast Cancer Patients with Biomarker Assays.” P.I. Philip Agop Philip, 5% effort. 2/18/04 – 2/28/06. Bristol-Myers Squibb, ImClone Systems, Inc, $105,955 “A Phase III Randomized, Open label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-line Treatment in Patients with Metastatic EGFR-Positive Colorectal Carcinoma.” 3/15/04 – 3/14/09. OSI Pharmaceuticals, $38,828, “A Randomized, Open Label, Phase II Study of OSI-7904L vs. 5-FU/LV as First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract.” P.I. Philip Agop Philip, 5% effort, 7/30/04 – 12/31/10. Aventis, and Sanofi, $334,650, “A Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer.” P.I. Philip Agop Philip, 4% effort, 12/1/04 – 12/31/08. Bristol-Myers Squibb, $105,486, “A Phase III Randomized, Multicenter Study of Cetuximab, Oxaliplatin, 5-FU, and Leucovorin vs. Oxaliplatin, %-FU, and Leucovorin in Patients with Previously Treated Metastatic, EGFR-positive Colorectal Carcinoma.” P.I. Philip Agop Philip, 5% effort, 7/12/04 – 12/31/10. Internal Medicine Department Seed Money Grant, $25,000. “Differential Gene Expression Profiling between Primary and Secondary Tumor Sites in Patients with Pancreas Cancer.” P.I. Dr Philip, 6/1/05 – 5/31/06. NIH, $1,862,975, “Molecular Approaches to Diet and Pancreatic Cancer Prevention.” P.I. Dr. Fazlul Sarkar, Dr Philip Co-Clinical PI, Pending. Pfizer, $320,000, “Phase II study of FOLFIRI, bevacizumab and enzastaurin in patients with metastatic colorectal cancers”, PI Dr Philip, Pending. Philip A. Philip, M.D.
Publications
Page One

PUBLICATIONS:
Original Observations in Peer-Reviewed Journals
1.
Philip, P.A., Roberts, M.S., Rogers, H.J. A Rapid Method for the Determination of Acetylation Phenotype Using Dapsone. British Journal of Clinical Pharmacology. 17:465-69, 1984. Cartwright, R.A, Philip, P.A., Rogers H.J., Glashan, R.W. Genetically Determined Debrisoquine Oxidation Capacity in Bladder Cancer. Carcinogenesis. 5: 1191-92, 1984. Philip, P.A., Gayed, S.L., Roger, H.J., Crome, P. Influence of Age, Sex and Body Weight on the Dapsone Acetylation Phenotype. British Journal of Pharmacology. 23:709-713, 1987. Ledermann, J.A., Crawford, S.M., Philip, P.A., Bagshawe, K.D. Curable Metastatic Cancer in Young Women. British Medical Journal. 295: 399-452, 1987. Philip, P.A., Rogers, H.J., Millis, R.R., Rubens, R.D., Cartwright, R.A. Acetylator Status and its Relationship to Breast Cancer and Other Diseases of the Breast. European Journal of Cancer and Clinical Oncology. 23:1701-06, 1987. Philip, P.A., Rogers, H.J., Harper, P.G. Acetylation and Oxidation Phenotypes in Malignant Lymphoma. Cancer Chemotherapy and Pharmacology. 20:235:238, 1987. Philip, P.A., James, C.A., Rogers, H.J. Determination of Debrisoquine Metabolic Ratio From Hourly Urine Collections in Healthy Volunteers. British Journal of Clinical Pharmacology. 24:827- 29, 1987. Philip, P.A., Fitzgerald, D.L., Cartwright, R.A., Peake, M.D., Rogers, H.J. Polymorphic N-acetylation Capacity in Lung Cancer. Carcinogenesis. 9:491-3, 1988. Philip, P.A., James, C.A., Lewis, L.D., Rogers, H.J. Relationship Between Ifosfamide Plasma Clearance and the Debrisoquine Oxidation Status. Cancer Chemotherapy and Pharmacology. 22:321-24, 1988. Hitchins, R.N., Philip, P.A., Wignall, B., Newlands, E.S., Begent, R.H.J., Rustin, G.J.S., Bagshawe, K.D. Bone Disease in Testicular and Extragonadal Germ Cell Tumors. British Journal of Cancer. 58:793-96, 1988. Philip, P.A., Rogers, H.J. Effect of Cancer Chemotherapy on Dapsone N-acetylation in Man. Cancer Chemotherapy and Pharmacology. 23:395-96, 1989. Philip, P.A., James, C.A., Rogers, H.J. The Influence of Cimetidine on Debrisoquine 4-Hydroxylation in Extensive Metabolizers. European Journal of Clinical Pharmacology. 36:319-21, 1989. Philip A. Philip, M.D. Publications Page Two 13. Kelly, M.P., Rustin, G.J.S., Ivory, C., Philip, P.A., Bagshawe, K.D. Respiratory Failure Due to Choriocarcinoma: A Study of 103 Dyspnoeic Patients. Gynaecologic Oncology. 38:149-154, 1990. P.A., Bagshawe, K.D., Searle, F., Newlands, E.S., Begent, R.H.J., Adam, T. In Vivo Uptake of 131I-5-Iodo-2-Deoxyuridine by Malignant Tumors in Man. British Journal of Cancer. 63:134-35, 1991. P.A., Carmichael, J., Harris, A.L. Convulsions and Cortical Blindness Following Therapy with Cisplatin. British Medical Journal. 302:416, 1991. P.A., Rustin, G.J.S., Ledermann, J.A., Begent, R.H.J., Bagshawe, K.D. Weekly Etoposide, Methotrexate, and Actinomycin D, Alternating with Cyclophosphamide Plus Vincristine (EMA/CO); A Phase II Study in Advanced Gastric Carcinoma. Clinical Oncology. 3:214-16, 1991. P.A., Joel, S., Monkman, S.C., Dolega-Ossowski, E., Tonkin, K., Carmichael, J., Idle, J.R., Harris, A.L. A Phase I Study on the Reversal of Multidrug Resistance (MDR) in Vivo: Nifedipine Plus Etoposide. British Journal of Cancer. 65:267-270, 1992. Rustin, J.R., Stratford, M.R., Lamont, A., Bleehen, N., Philip, P.A., Howells, N., Watfa, R.R., Slack, J.A. Phase I Study of Intravenous 4-Hydroxyanisole. European Journal of Cancer. 28A(8/9): 1362-64, 1992. Stuart, N.S.A., Philip, P.A., Harris, A.L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E.A., Carmichael, J. High-dose Tamoxifen as an Enhancer of Etoposide Cytotoxicity. Clinical Effects and In Vitro Assessment in P-Glycoprotein Expressing Cell Lines. British Journal of Cancer. 66:833-39, 1992. Philip, P.A., Carmichael, J., Tonkin, K., Buamah, P.K., Britton, J., Dowsett, M., Harris, A.L. Hormonal Treatment of Pancreatic Carcinoma: A Phase II Study of LHRH Agonist Goserelin Plus Hydrocortisone. British Journal of Cancer. 67:379-82, 1993. Philip, P.A., Kaklamanis, L., Carmichael, J., Tonkin, K., Morrison, H., Gatter, K., Harris, A.L. The Influence of High Dose Hydroxyurea on the Incorporation of 5-Iodo-2-Deoxyuridine (IUdR) by Human Bone Marrow and Tumor Cells In Vivo. British Journal of Cancer, 67:644-49, 1993. Philip, P.A., Campbell, C.H., Carmichael, J., Rea, D., Mitchell, K., Taylor, D.J., Stuart, N.S.A, Dennis, I., Rajagopalan, B., Ganesan, T., Radda, K., Harris, A.L. A Phase I Study of the Left-Shifting Agent BW12C79 Plus Mitomycin C and the Effect on the Skeletal Muscle Metabolism Using 31P Magnetic Resonance Spectroscopy. Cancer Research. 53:5649-53, 1993. Philip, P.A., Rea, D., Thieves, P., Carmichael, J., Stuart, N.S.A., Rockett, H., Talbot, D.C., Ganesan, T., Pettit, G.R., Balkwill, F., Harris, A.L. Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo (see Editorial Comments). Journal of National Cancer Institute. 85:1812-18, 1993. Philip A. Philip, M.D. Publications Page Three 24. Philip, P.A., Kaklamanis, L., Ryley, N., Wolf, R., Harris, A.L., Stratford, I., Carmichael, J. Expression of Xenobiotic-Metabolizing Enzymes in Primary and Secondary Hepatic Tumors in Man. International Journal of Radiation Oncology Biology Physics. 29:277-83, 1994. P.A., Carmichael J., Tonkin T., Ganesan T.A., Harris A.L. A Phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. European Journal of Cancer, 30A: 1027-1029, 1994. P.A. and Ajani J. Has combined modality therapy improved the outlook in carcinoma of Carmichael J., Possinger K., Philip P.A., Beykirch M., Kerr H., Walling J., Harris A.L. Advanced Breast Cancer: A phase II trial with Gemcitabine. Journal of Clinical Oncology, 13:2731-2736, 1995. Carmichael J, Philip P.A., Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemotherapy and Pharmacology, 37:134-138, 1995. P.A., Souliotis V.L., Harris A.L., Salisbury A., Tates A.D., Mitchell K., Van Delft J. H.M., Ganesan T.S., Kyrtopoulos S.A. Methyl DNA adducts, DNA repair and HPRT mutations in peripheral white blood cell from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clinical Cancer Research, 2:303-310, 1996. Zalupski, M.M., Philip, P.A., LoRusso, P.M., Shields, A.F. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemotherapy and Pharmacology, 40:225-227, 1997. P.A., Flaherty, L.E. Interleukin-2 in the treatment of malignant melanoma. Seminars in P.A., Zalupski M.M., Gadgeel, S., Hussain, M., Shields, A.F. A Phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Seminars in Oncology, 24:S19-S26, 1997. Macaulay, V.M., O’Byrne, K.J., Green, J.A., Philip, P.A., McKinely, L., LaCreta, F.P., Winograd, B., Ganesan, T.S., Harris, A.L. and Talbot, D.C. Phase I study of the Mitomycin C analogue BMS-181174. British Journal of Cancer, 77(11): 2020-2027, 1998. Zalupski, M.M., Shields, A.F., Philip, P.A., Kraut, M.J., LoRusso, P.M., Heilbrun, L.K., Vaitkevicius, V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs, 16: 93-96, 1998. Macaulay, V.M., O’Byrne, K.J., Green, J.A., Philip, P.A., McKinely, L., LaCreta, F.P., Winograd, B., Ganesan, T.S., Harris, A.L. and Talbot, D.C. Phase I study of the Mitomycin C analogue BMS-181174. British Journal of Cancer, 77(11): 2020-2027, 1998. Shields, A.F., Philip, P.A., LoRusso, P.M., Ferris, A.M., Zalupski, M.M. Phase II study of CI-958 in colorectal cancer. Cancer Chemotherapy and Pharmacology, 43:162-164, 1998 Philip A. Philip, M.D. Publications Page Four 37. Philip, P.A., Ali-Sadat, S., Kocarek, T., Akhtar, A., Doehmer, J., Chan, K.K. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism of cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 43: 59-67, 1999. P.A., Rea D, Mitchell K, Carmichael J, Harris AL, Talbot DC. A pilot study of increasing dose-intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony stimulating factor. Clinical Oncology, 11:84-89, 1999. P.A., Ibrahim, D., Zalupski, M., Arlauskas, P., Shields, A. Gemcitabine and UFT Plus Oral Calcium Folinate: Phase I Study. Oncology. 13(7), SUPPL. NO. 3:116-19, 1999. O’Byrne, K.J., Philip, P.A., Saunders, M.P., Propper, D.J., Braybrooke, J.P., Salisbury, A.J., Taylor, M.A., Ganesan, T.S., Talbot, D.C. and Harris, A.L. Modulation of 5-Fluorouracil and Folinic acid with Hydroxyurea in the Treatment of Metastatic Colorectal Carcinoma. Annals of Oncology. 10(8): 981-83, 1999. Zonder, J.A., Shields, A.F., Zalupski, M., Chaplen, R., Heilbrun, L.K., Philip, P.A. A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer. Clinical Cancer Research. 7:38-42, 2001. P.A., Zalupski, M. M., Vaitkevicius, V.K., Arlauskas, P., Chaplen, R., Heilbrun, L. K., Adsay, V., Weaver, D., Shields, A.F. Phase II Study of Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer. Cancer. 92:569-77, 2001. Merati, K., Siadaty, M.S., Sarkar, Andea, A., Sarkar, F, Mohammad, R.M., Philip, P.A., Shields, A.F., Vaitkevicius, V., Grignon, D.J., Volkan, A.N. Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and its Relationship to Pathologic and Clinical Parameters. American Journal of Clinical Oncology. 24:447-52, 2001. Mohammad, R.M., Adsay, N.V., Philip, P.A., Pettit, G.R., Vaitkevicius, V.K., Sarkar, F.H. Bryostatin 1 Induces Differentiation and Potentiates the Antitumor Effect of Auristatin PE in a Human Pancreatic Tumor (PANC-1) Xenograft Model. Anti-Cancer Drugs. 12:735-40, 2001. Vaishampayan, U.N., Ben-Josef, E., Philip, P.A., Vaitkevicius, V.K., Du, W., Levin, K., Shields, A.F. A Single Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies. International Journal of Radiation Oncology and Biologic Physics. 53:675-79, 2002. El-Rayes, B.F., Berenji, K., Schuman, P., Philip, P.A. Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. Five Case Reports and a Review of the Literature. Breast Cancer Research and Treatment. 76;111-116, 2002. Philip A. Philip, M.D. Publications Page Five 47. Pernick, N.L., Sarkar, F.H., Philip, P.A., Arlauskas, P., Shields, A.F., Vaitkevicius, V.K., Dugan, M.C., Adsay, N.V. Clinicopathologic Analysis of Pancreatic Adenocarcinoma in African Americans and Caucasians. Pancreas, 26:28-32, 2003. Al-Sukhun, S., Zalupski, M.M., Ben-Joseph, E., Vaitkevicius, V.K., Philip, P.A., Soulen, R, Weaver, D., Adsay, V., Heilbrun, L., Levin, K., Forman, J., Shields, A.F. Chemo-Radiotherapy in the Treatment of Regional Pancreatic Carcinoma: A Phase II Study. Am J Clin Oncol, 26(6): 543-649.2003. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D, Philip PA. Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer. Clinical Cancer Research, 9: 1705-1709, 2003. Gadgeel, S., Shields, A.F., Labadidi, S., Zalupski, M., Heilbrun, L., Chaplen, R., Philip, P.A. A Phase II Study of Paclitaxel and Carboplatin in Patients with Advanced Stomach Cancer. American Journal of Clinical Oncology. 26:37-41, 2003. Ali S, Aranha O, Li Y, Pettit G, Sarkar FH, Philip PA. Sensitization of Human Breast Cancer Cells to Gemcitabine by Protein Kinase C Modulator Bryostatin 1. Cancer Chemotherapy and Pharmacology, 52:235-246, 2003. Pernick NL, Adsay V, Carolin KA, Philip PA, Sipiesrski S, Bouwman D, Kosir MA White M, Visscher DW. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Newman LA. Patients Treated with Preoperative Chemotherapy Correlates with Breast Cancer Outcome. Annals of Surgical Oncology, 10:734-739, (Accompanying Editorial by B O Anderson, pp 713-715), 2003. El-Rayes BF, Zalupski M, Shields A, Vaishampayan U, Heilbrun LK, Adsay V, Philip PA. A Phase II study of gemcitabine, cisplatin and infusional 5-flourouracil in advanced pancreatic cancer. Journal of Clinical Oncology, 21:2920-2925, 2003. Li Y, Ali S, Philip PA, Sarkar FH. Direct Comparison of Microarray Gene Expression Profiles between Non-amplification and a Modified cDNA Amplification Procedure Applicable for Needle Biopsy Tissues. Cancer Detection and Prevention, 27:405-411, 2003. Puscheck, EP, Philip, PA, Jeyendran, RS. Male fertility preservation and cancer treatment. Cancer Treatment Reviews, 30:173-178, 2004. Simon M S, Du W, Flaherty L, Philip PA, Lorusso P, Mirec C, Smith D, Brown D. Factors associated with breast cancer clinical trials participation and enrolment at a large academic medical center. Journal of Clinical Oncology, 2004 Jun 1; 22(11): 2046-52. E Ben-Josef, AF Shields, U Vaishampayan, V Vaitkevicius, BF El-Rayes, P McDermott, J Burmeister, B Todd, PA Philip. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. International Journal of Radiation Biology and Physics, 2004 Jun; 15(6): 960-5.
Philip A. Philip, M.D. Publications Page Six 58. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA. A phase II trial of carboplatin and paclitaxel in advanced esophageal cancer. Annals of Oncology, 15: 960-965, 2004. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA. A phase II trial of carboplatin and paclitaxel in adenocarcinoma of unknown primary. American Journal of Clinical Oncology, 28(2):152-6. 2005. Li Y, Ellis K-L, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar F. Apoptosis inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genstein, a natural inhibitor of NF-kB in BxPC-3 pancreatic cancer cell line. Pancreas, 28(4): e90-95, 2004. Ali S, El-Rayes BF, Heilbrun LK, Sarkar F, Ensley JF, Kucuk O, Philip PA. Cytochrome P450 and glutathione transferase expression in squamous cell cancer. Clinical Cancer Research, 2004 Jul 1; 10(43): 4412-6. El-Rayes BF, Ibrahim D, Shields AF, LoRusso P, Zalupski M, Philip PA. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Investigational New Drugs, 23(1): 57-62, 2005. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and independent effects of celecoxib in pancreatic cancer cell lines. Molecular Cancer Therapeutics, 3(11): 1421-1426, 2004. Philip PA, MR, Mahoney, C Allmer, J Thomas, HC Pitot, EA Johnson, G Kim, R Donehower, T Fitch, PM. Fracasso, F Dawkins, C Erlichman. Phase II Study of Erlotinib (OSI-774) in Patients with Advanced Hepatocellular Cancer. Journal of Clinical Oncology, 23(27): 6657-63, 2005. El-Rayes B, Zalupski M, Vaishampayan U, Shields AF, Heilbrun, Philip PA. Phase II study of gemcitabine, cisplatin and celecoxib in patients with metastatic pancreas cancer. Investigational New Drugs, 23(6): 583-90, 2005. Talamonti MS, Small W, Mulcahy MF, Wayne J, Attaluri V, Colleti L, Zalupski MM, Hoffman J, Freedman GM, Kinsella T, Philip PA, TS, McGinn CJ. A multiinstitutional Phase II trial of Preoperative Full-dose Gemcitabine and Concurrent Radiation for Patients with Potentially Resectable Pancreatic Carcinoma. Annals of Surgical Oncology, 13(2): 1-9, 2006. El-Rayes BF, LoRusso P, Philip PA. A Phase I Study of Flavopiridol and Docetaxel. American Investigational New Drugs, 24:305-310, 2006. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH. Molecular evidence for increased anti-tumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Research, 65(19): 9064-72, 2005. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer and Treatment, 90: 25-31, 2005. Philip A. Philip, M.D. Publications Page Seven Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Research, 65: 6934-6941, 2005. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer, 2006 Jul 17; [Epub ahead of print]. Cote ML, Wenzlaff AS, Philip PA, Schwartz AG. Secondary cancers after a lung carcinoid primary: a population-based analysis. Lung Cancer, 52:273 – 279, 2006. Philip PA, Mahoney MR, Allmer, C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, and Erlichman C. Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer. Journal of Clinical Oncology, 24:3069–3074, 2006. Isacoff WH, Bendetti JK, Barstis JJ, Jazieh A-R, MD, Macdonald JS, Philip PA. Infusional 5-Flurouracil, Leucovorin, Mitomycin-C, and Dipyridamole in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma: A Phase II Trial of the Southwest Oncology Group (SWOG). Journal of Clinical Oncology, In Press. [An Editorial will also accompany the publication]. El-Rayes BF, Gadgeel S, Zalupski M, Shields AF, Lorusso P, Philip PA. A phase I study of gemcitabine and uracil-ftorfar (UFT)/ leucovorin. American Journal of Clinical Oncology, In Press. Thatai LC, Vishnubhotla P, Biernat L, Flaherty L, LoRusso P, Simon M, Stephens D, Vereeke K, Abrams J, Bouwman D, Philip PA. A phase II study of docetaxel, doxorubicin and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer. American Journal of Clinical Oncology, 29(5):484-489, 2006. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knoll JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM. A Phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. American Journal of Clinical Oncology, In Press. Lu H, Wang JJ, Chan KK, Philip PA. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. Xenobiotica, 36:367-385, 2006. El-Rayes BF, Gadgeel S, Shields AF, Manza S, LoRusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clinical Cancer Research, 12(23): 7059-7062, 2006. Philip PA, Mahoney MR, Allmer, C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, and Erlichman C. In reply to letter to editor. Journal of Clinical Oncology, In Press. Philip A. Philip, M.D. Publications Page Eight Review Articles 1. Philip, P.A., Harris, A.L. Molecular Aspects of Breast Carcinoma. Royal Society of Medicine. Current Medical Literature. pp 3-7, 1992. P.A., Harris, A.L. Potential for Protein Kinase C Inhibitors in Cancer Therapy. In, Chemotherapy: Concepts, Mechanisms, and New Targets for Chemotherapy. Ed; FM Muggia. 6:3-27, November 1995, Kluwer Academic Publishers, Boston, MA. P.A., Ajani, J. Gastro-Intestinal Malignancies in the Elderly. Cancer Bulletin, 47:218-223, P.A. Interleukin-2 and Malignant Melanoma. Expert Opinion on Investigational Drugs. Zonder, J., Philip, P.A. Pharmacology and Clinical Experience with Bryostatin 1: A Novel Anticancer Drug. Expert Opinion on Investigational Drugs. 8(12): 2189-2199, 1999. Gurjal, A., Philip, P.A., IL-2 in Cancer. Emerging Drugs: The Prospect for Improved Medicines. 5(3): 273-285, 2000. Philip, P.A., Flaherty, L. Biochemotherapy of Melanoma. Current Opinion in Clinical Oncology. 2(4): 314-321, 2000. Philip, P.A. Gemcitabine Platinum Combinations in Pancreatic Cancer. Cancer. 95:908-911, 2002. El-Rayes, B., Adsay, V., Philip, P.A. Pancreatic cancer: the evolving role of systemic therapy. Expert Opinion on Pharmacotherapy. 2:1939-1947, 2002. El-Rayes, B., Philip, P.A. Systemic Therapy for Advanced Pancreatic Cancer. Expert Review of Anticancer Therapy. 2:426-436, 2002. El-Rayes, B., Shields A.F., Vaitkevicius, V, Philip, P.A. Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation. 21:73-86, 2003. El-Rayes B, Philip PA. Systemic Therapy of Advanced Pancreas Cancer. Hematology and Oncology, 1(7): 430-434, July 2003. Philip PA. Current Strategies in Previously Untreated Patients with Advanced Colorectal Cancer. Physicians’ Education Resource, 7(3): 3-6, 2003. Philip PA. Experience with Docetaxel in the Treatment of Gastric Cancer. Seminars in Oncology. 32(suppl 4): S24-S38), 2005. [also authored the Introduction on pages 1 and 2 of the same issue]. Philip PA. Is EGFR Testing Necessary for Using Cetuximab in Patients with Advanced Colorectal Cancer? American Journal of Clinical Oncology Review, In Press. Philip PA. A New Era in the Treatment of Metastatic Colorectal Cancer. American Journal of Clinical Oncology Review, 5:10, suppl 8, pages 10-11, 2006 Philip A. Philip, M.D. Publications Page Nine Books and Chapters 1. Philip, P.A., Harris, A.L. Malignant Disease in Pregnancy. In, Oxford Textbook of Medicine, 3d Edition, (1995). Eds. Weatherall D., Ledingham J.G.G., Warell D.A. Oxford University Press, Oxford. pp. 1806-1808. Talbot, D.C., Philip, P.A. Drug Resistance. In, Treatment of Cancer. 3d edition. Eds. Price P. and Sikora K. Chapman and Hall, London. 1995, pp. 109-119. Philip, P.A., Ajani, J. Gastric Cancer. In, Medical Oncology a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 235-246. Philip, P.A., Milliken, R. Prostate Cancer. In, Medical Oncology, a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 419-432. Philip, P.A., Ajani, J. Esophageal Cancer. In, Medical Oncology, a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 225-234. Philip, P.A., Molecular Biology in the Diagnosis, Follow-up and Therapeutic Evaluation of Colorectal Cancer. In, Genetic Diagnosis in Medicine. Ed., J. Garcia-Foncillas, M.E. Armengod, J.M. Echevarria, A. Blasbond. University of Navarra Press, Pamplona. 1998. Flaherty, L.E., Philip, P.A. Biochemotherapy of Melanoma. In, Melanoma: Biologically Targeted Therapeutics. Ed., Ernest C Borden. Humana Press Inc., Totowa, New Jersey, pp. 259-285, 2002. A Molecular Medicine Resource, Elsevier, Inc. – Reviewed for Community Oncology, March, 2006 Philip, P.A., Internet-based Physician’s Information and Education Resource (PIER), “Pancreas Cancer Module,” American College of Physicians - American Society of Internal Medicine, 2004 - present. Ph.D. Thesis (1988). “Studies in Polymorphic Drug Metabolism in Cancer,” University of London, Philip A. Philip. Philip, PA. “Improvements in Gastric Cancer Therapy Options,” Medscape Conference Coverage. June 30, 2003. Available at http://www.medscape.com/viewarticle/457605. Philip, PA. Update on the GI ASCO symposium, Pancreas Cancer. Available at http://www.medscape.com/viewarticle/468972, 2004. Philip A. Philip, M.D. Published Abstracts Page One Published Abstracts 1. Philip P.A., Kaklamanis L., Morrison H., Gatter K.C., Carmichael J., Harris A.L. The influence of a continuous infusion of hydroxyurea (HU) on the uptake of 5-iodo-2-deoxyuridine (IUdR) by bone marrow and tumor cells in man. British Association of Cancer Research meeting in Manchester, England, April 1991. Lind M., Philip P.A., Margison J., et al. The effect of ifosfamide on antipyrine clearance in patients with non-small cell lung cancer. Proceedings of AACR, 32, 1991. P.A., et al. Expression of drug metabolising enzymes (DME) in primary hepatic tumors in man. British Association of Cancer Research (BACR) Spring meeting at University of Southampton, Southampton, England, March 1992. P.A. et al. A phase I/II study of left shifting agent BW12C and mitomycin C. Monitoring by magnetic resonance spectroscopy (MRS). Proceedings of the ASCO, 11, 1992. Carmichael J., Philip P.A., Rea D., et al. Gemcitabine: an active drug in advanced breast cancer. Results of a phase II study. Proceedings of ASCO, 11, 1992. Philip P.A., et al. Hormonal therapy in pancreatic carcinoma: A phase II study of LHRH agonist goserelin plus hydrocortisone. British Association of Cancer Research (BACR) spring meeting in University of Southampton, Southampton, England, March 1992. Philip P.A., Modulation of drug resistance with antimetabolites: the influence of high-dose hydroxyurea (HU) on the repair of cisplatin induced DNA damage. British Association of Cancer (BACR) spring meeting in March 1992, University of Southampton, Southampton, England, March 1992. Rea D., Harris A.L., Philip P.A., et al. Essential fatty acids in the treatment of metastatic carcinoma of the colon. British Association of Cancer Research (BACR) spring meeting in March 1992, University of Southampton, Southampton, England. P.A., et al. Phase I trial of bryostatin-1. Influence on the plasma concentrations of interleukin-6 and tumor necrosis factor-a. Proceedings of the AACR, 34, 1993. P.A., et al. High-dose hydroxyurea increases the formation of O6-methylguanine but not N7-methylguanine DNA adducts in lymphocytes from melanoma patients treated with dacarbazine without induction of HPRT mutations or micronuclei formation. EORTC/PAMM winter meeting in Brest/France, January 14-16, 1993. P.A., et al. Hydroxyurea increases the formation of O6-methylguanine (OMG) DNA adducts in lymphocytes from melanoma patients treated with dacarbazine (DTIC). The influence of dacarbazine on the induction of DNA mutations. Proceedings of ASCO, 12, 1993. Carmichael J., Possinger K., Philip P.A., et al. Difluorodeoxycytidine (gemcitabine): A phase II study in patients with advanced breast cancer. Proceedings of ASCO, 12, 1993. Philip A. Philip, M.D. Published Abstracts Page Two 13. Philip P.A., et al. Expression of xenobiotic-metabolizing enzymes (XMEs) by primary and secondary hepatic tumors in man. Eighth International Congress on Chemical Modifiers, Kyoto, Japan, June 1993. P.A., Talbot D., Rea D., et al. Phase I study of protein kinase C partial agonist, bryostative-1. EORTC Early Drug Development Meeting, June 23-26, 1993. Rotterdam, The Netherlands. Talbot D.C., Green J.A., Mitchell K., Smith K., Philip P.A., Stuart N., et al. Phase I study of the mitomycin C analogue BMY 25067. European Journal of Cancer. 29A. Supplement 6. S120, 1993. P.A., et al. 5-fluorouracil, a-interferon, cisplatin (FAP) and methotrexate (MTX) in patients (pts) with transitional cell carcinoma (TCC): results of a phase I trial. Proceedings of ASCO 13, A796, 1994. O'Byrne K.J., Philip P.A., Stuart N.S.A. et al. Increased dose-intensity of epirubicin and ifosfamide in small cell lung cancer using r-metHuG-CSF. British Journal of Cancer, Supplement XXI, Vol 69, 1994. Vallis K., Philip P.A., Rockett H., et al. Multidrug resistance reversal with toremifene in renal cell cancer. British Journal of Cancer, Supplement XXI, Vol 69, 1994. P.A., and Hsieh J.T. Correlation between an apoptosis-associated gene (TRPM-2) and apoptotic cell death induced by Adriamycin in a rat prostatic epithelial cell line (NbE). AACR special conference in cancer research: Basic and clinical aspects of prostate cancer, Palm Springs, CA, December 8-12, 1994. O'Byrne K.J., Philip P.A., et al. 5-Fluorouracil and folinic acid modulation with hydroxyurea in the treatment of metastatic colorectal cancer. BACR Spring meeting, Nottingham/England, April 2-5, 1995. British Journal of Cancer, Supplement, p. 10, A3.1. O'Byrne K.J., Philip P.A., et al. Modulation of 5-Fluorouracil and folinic acid with hydroxyurea in the treatment of metastatic colorectal cancer. Proceedings of ASCO, 14:172, 372A, 1995. P.A., Ali-Sadat, S., Kocarek, T., Doehmer, J. In vitro metabolism of cytotoxic drugs using V79 cells stably transfected with human cytochrome P-450 cDNAs. Proceedings of AACR, Abstract #2515, 1996. P.A., Ali-Sadat, S., Kocarek, T., Doehmer, J. The use of the V79 cells stably transfected with cytochrome P-450 cDNAs in studying the metabolism of cyclophosphamide and ifosfamide. Proc. ASCO, Abstract #A1588, 1996. P.A., Ali-Sadat S, Chen, K.K., Kocarek, T., Doehmer, J. Influence of differential metabolism of cyclophosphamide (CPA) on cytotoxicity in MCF-7 and V-79 cells. Proc. AACR, 1997. Philip A. Philip, M.D.
Published Abstracts
Page Three
25.
Philip, P.A., et al. Interactions of bryostatin 1 with tamoxifen, paclitaxel, and doxorubicin in human breast cancer cells. Proceedings of AACR, 1998. Philip, P.A., et al. Expression of cytochrome P450 enzymes in the oral mucosa of African-Americans (AA) and Caucasians (CC). Proceedings of AACR, 1998. P.A., Ali-Sadat, S., Chen, K.K., Kocarek, T., Doehmer, J. Influence of Differential Metabolism of Cyclophosphamide (CPA) on Cytotoxicity in MCF-7 and V-79 cells. Proceedings of AACR, 1997. 28. Philip, P.A., et al. Interactions of Bryostatin 1 with Tamoxifen, Paclitaxel, and Doxorubicin in Human Breast Cancer Cells. Proceedings of AACR, 1998. 29. Philip, P.A., et al. Expression of Cytochrome P450 Enzymes in the Oral Mucosa of African- Americans (AA) and Caucasians (CC). Proceedings of AACR, 1998. 30. Owainati, A., Zalupski, M., Shields, A., Hussain, M., Philip, P.A. Phase I Study of Liposomal Doxorubicin (Doxil) and Cyclophosphamide in Solid Tumors. Proceedings of ASCO, 1998. 28. Philip, P.A., Gadgeel, S., Shields, A., Zalupski, M., Hussain, M. Phase II Study of Paclitaxel and Carboplatin in Patients with Advanced Gastric and Esophageal Cancers. Proceedings of ASCO, 1998. Philip, P.A., Ali-Sadat, S., Alonso, M., Manji, H., Sarkar, F., Ensley, J. Bryostatin 1 Sensitizes Human Breast Cancer Cells to Gemcitabine (Gemzar). Abs. # 523, Breast Cancer Research and Treatment, 50 (3), 1998. 30. Biernat, L., Flaherty, L., Philip, P., Simon, M. A Phase II Study of the Combination of Taxotere, Doxorubicin, and Infusional 5-FU (TDF) in the Treatment of Locally Advanced Breast Cancer (LABC)- Preliminary Toxicity Data. Abs. # 550, Breast Cancer Research and Treatment 50 (3), 1998. P.A., Zalupski, M., Vaitkevicius, V.K., Arlauskas, P., Shields, A.F. Phase II Study of Gemcitabine and Cisplatin in Advanced or Metastatic Pancreatic Cancer. Proceeding of the Annual Meeting of ASCO, Atlanta, Georgia, May 1999. P.A., Li, Y., Alonso, M., Manji, H., Sarkar, F., Ensley, J., Ali, S. Sensitization of Human Breast Cancer Cells to Gemcitabine by Bryostatin 1. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999. P.A., Heilbrun, L., Lababidi, S., Vischer, D., Ali, S. Expression of Cytochrome P450 (CYP) Enzymes in Malignant and Morphologically Normal Human Breast Tissues. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999. Philip, P.A., Gadgeel, S., Hussain, M., Zalupski, M.M., Shields, A.F. Phase II Study of Carboplatin and Paclitaxel in Patients with Advanced Upper Gastrointestinal Cancers. Seminars in Oncology, Feb 1999, 141. Philip A. Philip, M.D. Published Abstracts Page Four 35. Andea, A., Philip, P.A., Shields, A.F., Vaitkevicius, V.K., Adsay, V. Is "Tail Carcinoma" a Different Entity? A Comparative Analysis of Resected Adenocarcinomas From the Head and Tail of Pancreas. Modern Pathology, 13(1), #1054, 2000. Feng, J., Vaitkevicius, V.K., Shields, A.F., Philip, P.A., Adsay, V. Perineural Invasion in Pancreatic Adenocarcinoma. Modern Pathology, 13(1), #1075, 2000. P.A., Pernick, N.L., Vaishampayan, U., Simon, M., LoRusso, P., Chaplen, Biernat, L., Flaherty, L. Phase II Study of Doxorubicin, Docetaxel, and 5-Fluorouracil (FAT) in Patients with Locally Advanced Breast Cancer. Proceedings of ASCO, 2000. Philip, P.A., Ensley, J. Heilbrun, L., Ali, S. Expression of Cytochrome p-450 Enzymes and Glutathione S-Transferase Pi in Tumoral Tissue From Patients with Head and Neck Cancers and its Relationship to the Tumoral Expression of p16. Proceedings of AACR, 2000. Feng, J., Vaitkevicius, V., Shields, A., Philip, P., Adsay, V. Perineural Invasion in Pancreatic Adenocarcinoma. Proceedings of 89th Annual Meeting, United States and Canadian Academy of Pathology, New Orleans, March 2000. Philip, P.A., Shields, A.F., Zalupski, M.M., Foster, B., Arlauskas, P., Adsay, V., Vaitkevicius, V.K. Phase II Study of Gemcitabine, 5-Fluorouracil and Cisplatin in Patients With Advanced Pancreatic Cancer. Pancreas, 4(21), 2000. Pernick, N.L., Sarkar, F., Arlauskas, P.L., Philip, P.A., Shields, V.K., Vaitkevicius, V.K., Adsay, V. FAS and FAS Ligand Expression in Pancreatic Adenocarcinoma. Pancreas, 4(21), 2000. Philip, PA, Ensley, J., Heilbrun, L., Ali, S. Expression of Cytochrome P-450 Enzymes and Glutathione S-transferase P1 in Peritumoral Tissue From Patients with Head and Neck Cancers and its Relationship to the Tumoral Expression of p16. Proceedings of the Annual Meeting of the AACR, San Francisco, 4/00. Dohmen, B.M., Shields, A.F., Dittmann H, Fersis N, Eschmann SM, Philip P, Reimold M, Machulla HJ, Bares. Use of [18F]FLT for breast cancer imaging. Proceedings of the Society of Nuclear Medicine Meeting, June 2001, Toronto. E. Ben-Joseph, E., Vaishampayan, U.N., Vaitkevicius, V.K., Levin, K.J., Philip, P.A., Shields, A.F. A Single Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies. Proceedings of ASCO, Volume 20, Abst 2324, 2001. Philip, P.A., Shields, A.F., Zalupski, M., El-Rayes, B., Adsay, V., Heilbrun, L., Arlauskas, P.L., Vaitkevicius, V.K. Gemcitabine, Cisplatin, and 5-Fluorouracil in Advanced Pancreas Cancer. Proceedings of ASCO, Volume 20, Abst 2341, 2001. Philip A. Philip, M.D. Published Abstracts Page Five 46. Philip, P.A., Shadan, Ali, Kraut, M.J., Sarkar, F. Flavopiridol Sensitizes Human Breast Cancer Cells to Gemcitabine. Annual Meeting of the American Association for Cancer Research, April, 2001. Al-Sukhun, S.A., Ali, S., Heilbrun, L., Lababidi, S., Philip, P.A. Protein Kinases C Isozymes are Differentially Expressed in Human Breast Carcinoma. Proceedings of the American Association of Cancer Research, 2002. Philip, P.A., Zalupski, M., El-Rayes, B., Adsay, V., Heilbrun, L., Vaitkevicius, V.K., Shields, A.F. Phase II Study of Gemcitabine, Cisplatin and Infusional 5-Fluorouracil in Patients with Metastatic Pancreatic Cancer. Proceedings of the American Society for Clinical Oncology (ASCO), 2002. O Kucuk, J McMichael, A Hatfield, M Holmes, H Razook, N Yousif, M Kraut, P Philip, A Shields, J Abrams. A new method of dose modification using a computerized decision support system to accurately predict the contribution of each drug to the toxicity of chemotherapy regimen. Proceedings of the American Society of Clinical Oncology (ASCO), #2590, 2002. L.A. Newman, N.L. Pernick, P. Philip, K. Carolin, D. Bouwman, M. Kosir, M. White and D.W. Visscher. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated with Preoperative Chemotherapy Predicts Breast Cancer Outcome. Annals of Surgery, 2002. B. Patel, B. F. El-Rayes, S. M. Gadgeel, P. Lorusso, P. A. Philip. A phase I study of flavopiridol and docetaxel. Proceedings of the American Society of Clinical Oncology (ASCO), #932, 2003. D. Ibrahim, B. F. El-Rayes, S. M. Gadgeel, P. Lorusso, P. A. Philip. A phase I study of the protein kinase C modulator bryostatin-1 and gemcitabine. Proceedings of the American Society of Clinical Oncology (ASCO), #930, 2003. B. F. El-Rayes, S. Ali, F. Sarkar, P. A. Philip. Protein kinase C (PKC): A target for therapy in pancreatic cancer. Proceedings of the American Society of Clinical Oncology (ASCO), #1091, 2003. P. A. Philip, S. M. Geyer, J. P. Thomas, H. C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, M. R. Mahoney, C. Erlichman Tolerability of OSI-774 (Tarceva) in locally advanced or metastatic hepatocellular cancer (HCC) and biliary (BILI) carcinomas: an interim report. Proceedings of the American Society of Clinical Oncology (ASCO), #1461, 2003. P. A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman. Proceedings of the Molecular Targets and Cancer Therapeutics international conference, 2003. P. A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman; OSI-774 (Tarceva) in patients (pts) with unresectable or metastatic hepatocellular carcinoma (HCC): A multi-center Phase 2 Consortium (P2C) study. Proceedings of the Molecular Targets and Cancer Therapeutics international conference, 2003. Philip A. Philip, M.D. Published Abstracts Page Six 57. Vishnubhotla, PS, Alsukhn S, Washington T, Freidman L, Flaherty L, Simon B, Yu B, Philip PA. Capecitabine is safe and tolerable in combination with radiation therapy in breast cancer. Breast Cancer Research and Treatment, Vol 82, Suppl 1, A169, 2003. McGinn CJ, Talamonti MS, Small W, Freedman GM, Berlin J, Kinsella TJ, Philip PA, Zalupski MM, Mulcahy MF, Meropol NJ, Chakraverthy A, Brell J, Balter JM, Normolle D, Benson AB, Lawrence TS. A Phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #96, page 89, 2004. El-Rayes, FB, Ali S, Sarkar F, Philip PA. Targeting the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX-2) pathways in pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #126, page 104, 2004. Ben-Josef, Shields A, Vaishampayan U, Vaitkevicius V, McDermott P, Burmeister J, Bossenberger T, Philip PA. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #163, page 122, 2004. Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C. Phase II trial of OSI-774 in patients with hepatocellular and biliary cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #174, page 173, 2004.
62.
HC. Pitot, K. M. Rowland, D. J. Sargent, P. A. Philip, E. P. Mitchell, R. M. Goldberg, S. R. Alberts;
N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-
fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC)
previously treated with 5FU. ASCO Proceedings, 2005, Ab #3506
K. M. Rowland, H. C. Pitot, D. J. Sargent, P. A. Philip, E. P. Mitchell, J. A. Mailliard, R. M.
Goldberg, S. R. Alberts. Results of 3rd line therapy on N9841: a randomized phase III trial of
oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts)
with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. ASCO
Proceedings, 2005, Ab #3519.
B. F. El-Rayes, M. M. Zalupski, A. F. Shields, L. K. Heilbrun, T. Bekaii-Saab, U. Vaishampayan, P.
A. Philip. A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer.
ASCO Proceedings, 2005, Ab #3677.
B. J. Schneider, J. Muler, P. Philip, G. Kalemkerian, B. El-Rayes, K. Griffith, M. Zalupski A phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP). ASCO Proceedings, 2005, Ab #4090 B. Patel, L. Heilburn, A. Khanna, R. Venkatramanamoorthy, A. Shields, P. Philip, M. Zalupski, B.
El-Rayes. CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated
with gemcitabine and cisplatin based chemotherapy. ASCO Proceedings, 2005, Ab #4189.
B. F. El-Rayes, A. F. Shields, U. Vaishampayan, L. K. Heilbrun, M. M. Zalupski, P. A. Philip. A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer. ASCO Proceedings, Ab #3584, 2006 Philip A. Philip, M.D. Published Abstracts Page Seven 68. T. J. Hobday, K. Holen, R. Donehower, J. Camoriano, G. Kim, J. Picus, P. Philip, R. Lloyd, M. Mahoney, C. Erlichman.A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. ASCO Proceedings, Ab #4043, 2006 W. Sun, J. Schwartz, A. Zhu, P. A. Philip, J. Metz, M. B. Thomas, Liver Cancer Research Group. Feasibility of multiinstittional live cancer registry. ASCO Proceedings, Ab #4146, 2006 J. Grandhi, P. A. Philip, T. Washington, A. F. Shields, U. Vaishampayan, L. K. Heilburn, R. Venkatramanamoorthy, B. F. El-Rayes. A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative negative patients. ASCO Proceedings, Ab #4153, 2006 S. M. Gadgeel, S. Ali, P. Philip, A. Wozniak, F. Sarkar. Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. ASCO Proceedings, Ab #7170, 2006 S M. Gadgeel, S Ali, P Philip, A Wozniak, and F Sarkar. Epidermal growth factor receptor (EGFR)
mutational status of non-small cell lung cancer cells (NSCLC) may determine the outcome of dual
blockade of EGFR and cyclooxygenase-2 (COX-2). AACR Meeting Abstracts, Apr 2006; 2006:
294.
Philip A. Philip, M.D. Presentations Page One Presentations: Invited and/or Refereed International or National Meetings 1. Philip P.A., Kaklamanis L., Morrison H., Gatter K.C., Carmichael J., Harris A.L. The influence of a continuous infusion of hydroxyurea (HU) on the uptake of 5-iod0-2-deoxyuridine (IUdR) by bone marrow and tumor cells in man. British Association of Cancer Research meeting in Manchester, England, April 1991. Philip P.A., et al. Expression of drug metabolizing enzymes (DME) in primary hepatic tumors in man. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992. Philip P.A., et al. Hormonal therapy in pancreatic carcinoma: A phase II study of LHRH agonist goserelin plus hydrocortisone. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992. Philip P.A., et al. Modulation of drug resistance with antimetabolites: The influence of high- dose hydroxyurea (HU) on the repair of cisplatin induced DNA damage. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992. Philip P.A., et al. Phase I trial of bryostatin-1. Influence on the plasma concentrations of interleukin-6 and tumor necrosis factor-a. AACR, Orlando, FL, 1993. Philip P.A., et al. High-dose hydroxyurea increases the formation of O6-methylguanine but not N7-methylguanine DNA adducts in lymphocytes from melanoma patients treated with dacarbazine without induction of HPRT mutations or micronuclei formation. EORTC/PAMM winter meeting in Brest, France, January 14-16, 1993. Philip P.A., et al. Expression of xenobiotic-metabolizing enzymes (XMEs) by primary and secondary hepatic tumors in man. Eighth International Congress on Chemical Modifiers, Kyoto, Japan, June 1993. Philip P.A., Talbot D., Rea, D., et al. Phase I study of protein kinase C partial agonist, bryostatin-1. EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, June 23- 26, 1993. Philip P.A., and Hsieh J.T. Correlation between an apoptosis-associated gene (TRPM-2) and apoptotic cell death induced by Adriamycin in a rat prostatic epithelial cell line (NbE). AACR special conference in cancer research: Basic and clinical aspects of prostate cancer, Special AACR meeting, Palms Springs, CA, December 8-12, 1994. P.A., Ali-Sadat, S., Kocarek T., Doehmer J. In vitro metabolism of cytotoxic drugs using V79 cells stably transfected with human cytochrome P-450 cDNAs. AACR meeting in Washington, D.C., April 1996 Philip A. Philip, M.D. Presentations Page Two 11. Philip P.A., Ali-Sadat, S., Kocarek T., Doehmer J. The use of the V9 cells stably transfected with cytochrome P-450 cDNAs in studying the metabolism of cyclophosphamide and ifosfamide. ASCO meeting in Philadelphia, PA May 1996. P.A., Zalupski, M.M., Gadgeel, S., Hussain, M., Shields, A. A phase II study of carboplatin and paclitaxel in patients with gastric and esophageal cancer. Fox Chase and Free University Symposium, Puerto Rico, March 12-14, 1997. P.A., Ali-Sadat, S., Chan, K.K., Kocarek, T., Doehmer, J. Influence of differential metabolism of cyclophosphamide (CPA) on cytotoxicity in MCF-7 and V-79 cells. AACR, San Diego, CA. April 1997. Philip, P.A., et al. Expression of cytochrome P450 enzymes in the oral mucosa of African-Americans (AA) and Caucasians (CC). AACR, 1998, New Orleans, LA. P.A., Gadgeel, S., Shields, A., Zalupski, M., Hussain, M. Phase II study of paclitaxel and carboplatin in patients with advanced gastric and esophageal cancers. Proceedings of ASCO, 1998. P.A., et al. Interactions of bryostatin 1 with tamoxifen, paclitaxel, and doxorubicin in human breast cancer cells. AACR, 1998, New Orleans, LA. Philip, P.A., Ali-Sadat, S., Alonso, M., Manji, H., Sarkar, F., Ensley, J. Bryostatin 1 sensitizes human breast cancer cells to gemcitabine (Gemzar). 21st Annual San Antonio Breast Cancer Symposium, TX, December 1998. Philip, M. Zalupski, V.K. Vaitkevicius, P. Arlauskas, A. Shields. Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer. Annual Meeting of ASCO, Atlanta, Georgia, May 1999. P.A., Li, Y., Alonso, M., Manji, H., Sarkar, F., Ensley, J., Ali, S. Sensitization of Human Breast Cancer Cells to Gemcitabine by Bryostatin 1. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999. Philip, P.A., Heilbrun, L., Lababidi, S., Vischer, D., Ali, S. Expression of Cytochrome P450 (CYP) Enzymes in Malignant and Morphologically Normal Human Breast Tissues. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999. 21. Seminar, U.S. Gemzar Investigator’s Meeting, “Phase II Study of Gemzar and Cisplatin in Advanced or Metastatic Pancreatic Cancer”, Memphis, TN, 3/98. Seminar, Fox Chase and Free University Symposium, “Phase II Study of Carboplatin and Paclitaxel in Gastric and Esophageal Cancer”. St. Thomas, Virgin Islands, March 25-28, 1998. Invited Speaker, “Protein Kinase C Modulators in Cancer Therapy: Bryostatin 1” Iowa Oncology Society Annual Meeting, Des Moines Oct 2, 1998. Invited Speaker, MD Anderson Cancer Center ORZEL Investigators Meeting and Consensus Conference, Boca Raton, Florida Oct. 16, 1998. Invited Speaker, 2nd International Symptom on Molecular Diagnosis in Medicine, “Molecular Biology in the Diagnosis and Treatment of Colo-Rectal Cancer”, Madrid, Spain, November 26, 1998. Invited Speaker, Western Massachusetts Chapter of Oncology Nursing Society, “Colo-Rectal Cancer”, December 12, 1998. Fox Chase Cancer Center meeting, "Update on Carboplatin and Taxol in Upper GI and Unknown Primary Cancers", Lanai/Hawaii, 3/1999. Gemzar Investigators' Meeting, "Phase I Study of Gemzar and Orzel", New Orleans, 3/1999. Gemzar Investigators' Meeting, "Phase II Study of Gemcitabine and Cisplatin in Advanced Pancreatic Cancer", New Orleans, 3/1999. Lecture, Dr Cobau’s Group in Toledo, “Advances in the Treatment of Pancreas Cancer”, January 14, 1999. Tumor Board, Bixby Medical Center, Adrian, Ohio, “Updates on the Treatment of Advanced Breast Cancer”, February 17, 1999. Lecture, Oxford Pain Course, Somerville College, University of Oxford, United Kingdom, “ Role of Bisphosphonates in Management of Cancer Pain”, 11/90. Department of Internal Medicine, St. Joseph Hospital, (Pontiac, MI.). “Colo-rectal and Primary Hepatic Cancers”, 3/96. Seminar, Gene Therapy Journal Club, Barbara Ann Karmanos Cancer Institute, Detroit, MI., 5/96. Seminar, Pancreas Cancer Group, Barbara Ann Karmanos Cancer Institute, Detroit, MI., 6/96. Grand Rounds, “Clinical Dilemmas”, Division of Hematology and Oncology, Detroit, MI., 10/96. Seminar, “Expression of Xenobiotic-Metabolizing Enzymes in Tonsilar Tissues”, Institute of Chemical Toxicology, Detroit, MI., 12/96. Grand Rounds, “Colo-Rectal Cancer”, Department of Internal Medicine, St. Joseph’s Hospital, Pontiac, MI., 3/97. Seminar, Breast Multidisciplinary Conference. “Mechanisms of Drug Resistance in Human Breast Cancer, Detroit, MI, May 15, 1997. Grand Rounds, Department of Medicine, “Advances in Colo-Rectal Cancer”, Harper Hospital, Detroit, MI., 7/97. Seminar, “Drug-Metabolizing Enzymes”, Mechanisms of Drug Resistance Group, Barbara Ann Karmanos Cancer Institute, Detroit, MI., 12/97. Grand Rounds, “Pancreatic Cancer”, Detroit Mercy Hospital, Internal Medicine Rounds, Detroit, MI., 1/98. Philip A. Philip, M.D. Presentations Page Five 43. Seminar, “Role of Cytochrome P450 3A4 Enzyme in the Pharmacogenetics of Cyclophosphamide”. Kresge Eye Institute, Detroit, MI., 3/98. Grand Rounds, “Colo-Rectal Cancer”, Department of Internal Medicine, St. Joseph’s Hospital, Pontiac, MI., 3/98. Seminar, “Pancreatic Cancer”, Detroit Mercy Hospital, Department of Internal Medicine, Detroit, MI, April 15, 1998. Seminar, “AACR”, Mechanisms of Drug Resistance Group, Karmanos Cancer Institute, June 1998. Grand Rounds, Department of Medicine, “Advances in the Therapy of Pancreatic Cancer”, Hutzel Hospital, Sept 11, 1998. Seminar, “Bryostatin and Gemcitabine”, Mechanisms of Drug Resistance Group, Sept 23, 1998 Seminar, Pancreas Group at Karmanos Cancer institute, “Phase II Study of Gemcitabine and Cisplatin”, January 22, 1999. Talk, Drug Discovery Program, Karmanos Cancer Institute, “Updates on the Treatment of Pancreas Cancer”, January 27, 1999. Internal Residency Program, "Colo-Rectal Cancer", St. Joseph Hospital, Pontiac, 4/2/1999. Breast Program, Karmanos Cancer Institute, "Role of Carcinogen Metabolizing Enzymes in Susceptibility and Response to Therapy", Karmanos Cancer Institute, 4/7/1999. Grand Rounds, "Reducing the Incidence of Breast Cancer in Women with High Risk", St Mary's Hospital, Livonia, May 26, 1999. Annual Oncology and ASCO Review Course, "Update in Gastrointestinal Malignancies", Karmanos Cancer Institute, Ritz Carlton Hotel, Dearborn, MI, June 12, 1999. Grand Rounds, "Advances in the Therapy of Metastatic Breast Cancer", St Mary's Hospital, Livonia, July 28, 1999. Invited Speaker, Detroit Gilda's Club, "Colo-Rectal Cancer", August 9, 1999. Grand Rounds, "Advances in the Treatment of Pancreatic Cancer", Division of Hematology and Oncology, Cancer Center, University of Alabama at Birmingham, September 16, 1999. Lecture, "Advances in the Treatment of Metastatic Breast Cancer", Pharmacy, Akron General Hospital, Akron, Ohio, November 1999. Lecture, "Advances in the Chemotherapy of Pancreas Cancer", Premiere Pancreas Support Group Meeting, Karmanos Cancer Institute, February 12, 2000. Philip A. Philip, M.D. Presentations Page Six 60. Grand Round, "Pancreatic Cancer", Department of Internal Medicine, Wayne State University, March 1, 2000. Tumor Board, "Pancreatic Cancer", North Oakland Medical Center, Pontiac, MI, March 9, 2000. Lecture, “Taxanes in Breast Cancer”, Annual Meeting of the Association for Kerala Medical Graduates, Chicago, IL, July 15, 2000. Lecture, “Monitoring the Effects of Therapy in Early Breast Cancer”, 1st Annual Breast Cancer Symposium, Wayne State University, Dearborn, MI, September 29, 2001. Lecture, “Colo-Rectal Cancer”, St Joseph Hospital, Pontiac, MI, March 22, 2000. Seminar, “Advances in the Treatment of Breast Cancer”, Beth Israel Hospital, Boston, MA, June 2000. P.A., Shields, A.F., Zalupski, M.M., Foster, B., Arlauskas, P., Adsay, V., Vaitkevicius, V.K. Phase II study of gemcitabine, 5-fluorouracil and cisplatin in patients with advanced pancreatic cancer. Joint Annual Meeting of the American Pancreatic Association and the International Association of Pancreatology, Nov 1-5, 2000, Chicago, IL. PA, Ensley J, Heilbrun L, Ali S. Expression of cytochrome P-450 enzymes and glutathione S-transferase P1 in peritumoral tissue from patients with head and neck cancers and its relationship to the tumoral expression of p16. Annual Meeting of the AACR, San Francisco, 4/00. PA, Shadan Ali, Michael J. Kraut, Fazlul Sarkar. Flavopiridol sensitizes human breast cancer cells to gemcitabine. Annual meeting of the American Association for Cancer Research, April, 2001. 69. Al-Sukhun SA, Ali S, Heilbrun L, Lababidi S, Philip PA. Protein kinases C Isozymes are Differentially Expressed in Human Breast Carcinoma. Annual Meeting of the American Association of Cancer Research, 2002. P.A. Philip, M. Zalupski, B. El-Rayes, V. Adsay, L. Heilbrun, V.K. Vaitkevicius, A. Shields. Phase II study of gemcitabine, cisplatin and infusional 5-fluorouracil in patients with metastatic pancreatic cancer. Annual Meeting of the American Society for Clinical Oncology (ASCO), Orlando, 2002. Lecture, “Pancreatic Cancer,” Memphis Cancer Center, Memphis, TN, August 28, 2000. Lecture, “DNA repair genes in breast cancer,” Annual Breast Retreat, Karmanos Cancer Institute, September 2000. Lecture Series, “Chemotherapy of Pancreatic Cancer,” October 11, 2000, Metro Health Center, Cleveland Ohio. Philip A. Philip, M.D. Presentations Page Seven 74. Annual Breast Lecture, “Advances in the Therapy of Breast Cancer,” Baptist Health System, Montgomery, AL, September 25, 2000. Lecture, “Advances in the Therapy of Colorectal Cancer,” Bixby Cancer Center, Adrian. MI, October 2000. Tumor Board and presentation, “Advances in the Diagnosis and Therapy of Pancreatic Cancer,” Tampa, FL, November 9, 2000. Lecture, “Multimodality Therapy of Pancreatic Cancer,” Pasco-Hernando ONS Chapter, Tampa, FL, November 9, 2000. Lecture, “Colo-Rectal Cancer,” 2nd Annual Update in Cancer and Hematology for the Primary Care Physician, Wayne State University and Karmanos Cancer Institute Symposium, November 18, 2000. Lecture, “Therapy of Pancreas Cancer,” Fellows Journal Club, William Beaumont Hospital, Royal Oak, MI, November 21, 2000. Lecture, “New Therapies for Pancreas Cancer” Drug Discovery Program, Karmanos Cancer Institute, November, 2000. Grand Round, “New Drug Development in Pancreas Cancer,” Southwestern University Medical School, Dallas, TX, December 1, 2000. Symposium, US Gemzar Investigators Meeting, "Phase I Study of Gemzar and UFT/Leucovorin," San Antonio, TX, March 2, 2000. Symposium, US Gemzar Investigators Meeting, "Gemcitabine, 5-Fluorouracil, and Cisplatin in Patients with Advanced Pancreatic Cancer,” San Antonio, TX, March 2, 2000. Lecture, Advances in the Chemotherapy of Stomach Cancer,” 2nd International Congress on Surgery of Stomach and Esophagus Cancers” Porto, Portugal, May 9, 2000. Fellow’s Core Lecture Series, “Herceptin,” Oncology Fellowship Program, WSU, January, 2001. Grand Round, “Developments in the Treatment of Colorectal Cancer,” St. Joseph Hospital, Ypsilanti, MI, March 7, 2001. Grand Round, “Advances in the Therapy of Colorectal Cancer,” Oakwood Hospital, Dearborn, MI, March 20, 2001. Grand Round, “New Therapies in Breast Cancer,” Providence Hospital, Southfield, MI, March 29, 2001. Grand Round, “Pancreatic Cancer,” North Michigan Hospital, Petoskey, MI, April 23, 2001. Philip A. Philip, M.D. Presentations Page Eight 90. Lecture, “ASCO 2001, Breast Cancer,” Good Samaritan Hospital CME activity, Dayton, OH, May 30, 2001. Lecture, “Annual Review in GI Oncology and ASCO Update,” Karmanos Cancer Institute and Wayne State University, Dearborn, MI, June 2, 2001. Lecture, “Gastrointestinal Cancers, ASCO 2001,” McLaren Regional Cancer Center, Flint, MI, June 6, 2001. Lecture, “Neoadjuvant Chemotherapy for Breast Cancer,” Grand Rounds, Elkhart Hospital, Elkhart, IN, August 8, 2001. Lecture, “Developments of Therapy of Early Breast Cancer,” Tumor Board, St. John’s Hospital in Macomb, MI, September 21, 2001. Lecture, “Neoadjuvant Chemotherapy in Operable Breast Cancer”, Grand Rounds, Michigan State University, East Lansing, MI, September 27, 2001. Lecture, “Monitoring Effects of Chemotherapy,” First Annual Breast Cancer Symposium of Karmanos Cancer Institute, Detroit, MI, September 28, 2001. Lecture, “Developments in the Systemic Therapy of Early Breast Cancer,” Tumor Board, St. Joseph Mercy Hospital, Ypsilanti, MI, October 3, 2001. Discussant, Tumor Board, St. Joseph Mercy Hospital, Macomb, MI, October 10, 2001. Lecture, “New Drug Development in Pancreas Cancer,” Grand Rounds, University of Michigan, Ann Arbor, MI, October 12, 2001. Grand Round, “Colorectal Cancer,” Bixby Cancer Center, Adrian, MI, October 17, 2001. Lecture, “Gastro-Intestinal Malignancies,” Oncology Board Review Course, Michigan Hematology and Oncology Society, Novi, MI, October 17, 2001. Lecture, “Neoadjuvant Chemotherapy for Breast Cancer,” Tumor Board, St. Joseph Mercy Hospital, Pontiac, MI, October 22, 2001. Fellows Core Lecture, “Pancreas Cancer,” Oncology Fellowship Training Program at WSU, Detroit, MI, December 7, 2001. Lecture, “San Antonio Breast Cancer Symposium,” Breast Tumor Board, Karmanos Cancer Institute, Detroit, MI, December 17, 2001. Symposium on New Strategies and Future Directions for the Treatment of Metastatic Colorectal and Breast Cancer, “Advances in the Therapy of Breast Cancer,” Houston, TX, January 13, 2001. Philip A. Philip, M.D. Presentations Page Nine 106. Invited Speaker,” Colorectal Cancer,” Duke Comprehensive Cancer Center Symposium, Pinehurst, NC, October 13, 2001. Spring Phase I Investigators’ Meeting, “Phase I Study of Bryostatin 1 and Gemcitabine (Gemzar),” National Cancer Institute, Bethesda, Maryland, March 18, 2002. Lecture, “Recent Advances in Pancreas Cancer,” Division of Gastroenterology, Department of Internal Medicine, Wayne State University, Detroit, MI, March 20, 2002. Lecture, “Primary and adjuvant therapy of stomach cancer,” III Reuniao Internacional De Actualizacao Em Cirurgia Do Esofago E Do Estomago,” Granja, Portugal, 15th April, 2002. Lecture, “Neoadjuvant therapy of esophagus cancer,” III Reuniao Internacional De Actualizacao Em Cirurgia Do Esofago E Do Estomago,” Granja, Portugal, 16th April, 2002. Lecture, “Advances in Breast Cancer Therapy,” Semi-annual meeting of the South Carolina Hematology and Oncology Society, Charleston, SC, April 26, 2002. 112. Lecture, “Gemcitabine-based Combination Chemotherapies,” Global Eli Lilly Meeting, Indianapolis, IN, May 17, 2002. 113. Grand Rounds, “Update from San Antonio Breast Cancer Symposium,” St. Vincent’s Hospital, Toledo, OH, January 24, 2002. Breast Tumor Board, “Molecular Monitoring of the Effects of Chemotherapy,” Karmanos Cancer Institute, Detroit, MI, February 4, 2002. Tumor Board, “Advances in the Neoadjuvant Chemotherapy of Breast Cancer,” St. Joseph Mercy Hospital, Ypsilanti, MI, March 6, 2002. Lecture, “Pancreas Cancer,” Tumor Board, Petoskey, MI, May 30, 2002. Grand Rounds, “COX-2 as an emerging target for the prevention and treatment of colorectal cancer,” Henry Ford Hospital, Detroit, MI, August 2, 2002. Lecture, “Utilization of Oral Agents in GI Carcinoma: Current and Future Strategies,” Third Annual Cancer Symposium, Mercy Cancer Care and St Joseph Mercy Oakland, Troy, MI, Sept 12, 2002. Grand Rounds, “Management of Early Breast Cancer,” Northwestern University, Chicago, IL, Lecture, “Adjuvant and Neoadjuvant Chemotherapy of Breast Cancer,” Society of Hematology and Oncology of Ohio, Columbus, OH, October 17, 2002. Philip A. Philip, M.D. Presentations Page Ten 121. L.A. Newman, N.L. Pernick, P. Philip, K. Carolin, D. Bouwman, M. Kosir, M. White and D.W. Visscher. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated with Preoperative Chemotherapy Predicts Breast Cancer Outcome. Society of Surgical Oncology, Annual Meeting, 2002. Lecture, “Chemotherapy of Metastatic Breast Cancer,” Midwestern Medical Center, Zion, IL, Lecture, “Advances in the Chemotherapy of Pancreas Cancer,” Ohio State University, Columbus, Session Chair, “Surgical Therapy of Pancreas Cancer,” 16th International Symposium on Recent Advances in Pancreatic Cancer, National Cancer Hospital of Japan, Tokyo, Japan, January 23, 2003. Lecture, “Treatment of Metastatic and Recurrent Pancreas Cancer,” 16th International Symposium on Recent Advances in Pancreatic Cancer, National Cancer Hospital of Japan, Tokyo, Japan, January 24, 2003. Lecture, “Development of Systemic Therapies of Pancreas Cancer”, Tokyo University of Women, Department of Surgery, Tokyo, Japan, January 27, 2003. Tumor Board, “Developments in the Therapy of Early Breast Cancer,” Jupiter Medical Center, West Lecture, “Current Trends in the Treatment of Advanced Colorectal Cancer,” Fox Chase Cancer Center annual meeting, Lanai, HI, March 25, 2003. Chairperson, GI cancer session, Fox Chase Cancer Center Annual Meeting, Lanai, HI, March 25, Grand Rounds, “Treatment of Colorectal Cancers,” The Cleveland Clinic, Cleveland, OH, March 28, 2003. Lecture, “New Trends in the Treatment of Advanced Colorectal Cancer,” GI Symposium, Ohio State University, Columbus, OH, 4/26/03. Lecture, “Neoadjuvant Chemotherapy of Breast Cancer,” Cooper Clinic, UAB, Birmingham, AL, May 8, 2003. Lecture, “Update on Pancreas Cancer,” Promedica Health System CME Department, Toledo, OH, May 14, 2003. Lecture, “Neoadjuvant Chemotherapy of Breast Cancer,” Fellows Meeting, Cancer Center, Oklahoma University, Oklahoma City, OK, May 16, 2003. Lecture, “Pancreas Cancer, An Update,” Gastrointestinal Cancer Symposium, Wayne State University, Dearborn, MI, May 17, 2003. Philip A. Philip, M.D. Presentations Page Eleven 136. Visiting Professor, Tumor Board, St Luke’s Hospital and Health Science Center, Milwaukee, WI, May 21, 2003. Lecture, “New Developments in the Treatment of Colorectal Cancer,” the Meeting of the Indiana Oncology and Hematology Consultants, Indianapolis, IN, May 29, 2003. Lecture, “Gastrointestinal Tumors,” Annual Review in Oncology and ASCO Update, Wayne State University/University of Michigan, The Michigan Society of Hematology and Oncology, Dearborn, MI, June 21st, 2003. Poster Presentation, B. F. El-Rayes, S. Ali, F. Sarkar, P. A. Philip. Protein Kinase C (PKC): A target for therapy in pancreatic cancer. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 1, 2003. Lecture, “Recent Advances in Gastric Cancer,” University of Columbia, Columbia, MO, July 13, 2003. Lecture, “Gastric Cancer,” Dayton VA Hospital, Dayton, OH, July 16, 2003. Oral presentation, “Phase II study of OSI-774 in Hepato-Biliary Cancers,” CTEP/NCI Meeting, Bethesda, MD, September 9, 2003. Lecture, “New Advancements in the Management of Breast Cancer,” The Arab-American Medical Association, Michigan Chapter, Troy, MI, September 18, 2003. Lecture, “Improving the Outcome of Colorectal Cancer: New Drugs,” Jaffar Oncology Conference, Strategies for Prevention and a Cure: Colorectal Cancer, Providence Cancer Institute, Dearborn, MI, September 19, 2003. Tumor Board, “Optimization of Chemotherapy for Early Stage Breast Cancer,” St. Joseph Hospital, Atlanta, GA, October 14, 2003. Lecture, “Drug therapy of Colorectal Cancer,” Ingham Regional Medical Center, Michigan State University, East Lansing, MI, November 7, 2003. B.F. El-Rayes, S. Ali, F. Sarkar, P. Philip. Cyclooxygenase 2 (COX-2) as a Target in Pancreatic Cancer. American Pancreatic Association Annual Meeting, Chicago, IL, November 2003. P. A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman Efficacy and Updated Tolerability of OSI-774 (Tarceva) in Patients with Locally Advanced or Metastatic Biliary (BILI) Carcinoma: A Multi-Center Phase 2 Consortium (P2C) study. NCI/EORTC/AACR Annual Targeted Therapies Meeting, Boston, MA, November 18-21, 2003. Philip A. Philip, M.D. Presentations Page Twelve 149. Oral presentation, P.A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman. OSI-774 (Tarceva) in Patients (pts) with Unresectable or Metastatic Hepatocellular Carcinoma (HCC): A multi-center Phase 2 Consortium (P2C) study. NCI/EORTC/AACR Annual Targeted Therapies Meeting, Boston, MA, November 18-21, 2003. Lecture, “Colorectal Cancer,” Huron Valley Hospital, Commerce Township, MI, November 19, 2003. Lecture, “What is New in the Systemic Therapy of Colorectal Cancer,” St. Vincent Hospital, Indianapolis, IN, December 10, 2003. Tumor Board, “Advances in Colorectal Cancers,” St. Joseph Hospital, Pontiac, MI, January 7, 2004. Session Chair, “Pancreatic Cancer,” First Annual GI Cancer Symposium, ASCO, January 2004, San Francisco. Grand Rounds, “Angiogenesis Therapies,” Pittsburgh, PA, January 30, 2004. Poster presentation, El-Rayes, FB, Ali S, Sarkar F, Philip PA. Targeting the Epidermal Growth Factor Receptor (EGFR) and Cyclooxygenase 2 (COX-2) Pathways in Pancreatic Cancer, Gastrointestinal Cancers Symposium, San Francisco, CA, January 23, 2004. Poster presentation, Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C. Phase II Trial of OSI-774 in Patients with Hepatocellular and Biliary Cancer. 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, January 23, 2004. Lecture, “Colorectal Cancer,” Beaumont Hospital Fellowship Training Program, Royal Oak, MI, February 16, 2004. Lecture, “Colorectal cancer,” University of Tennessee at Memphis, Memphis, TN, March 2, 2004. Lecture, “Update of GI Cancer ASCO Symposium,” St. Joseph Mercy CME activity, Dearborn, MI, March 6, 2004. Lecture, “Angiogenesis as a Target in Colorectal Cancer,” University of Kentucky, Lexington, KY, April, 7, 2004. Lecture, “Pancreatic cancer,” Case Western University, Ireland Cancer Center, Cleveland, OH, April 14, 2004. Lecture, “Colorectal cancer,” Metrohealth Hospital, Cleveland, OH, April 22, 2004. Lecture, “Use of EGFR blockade in Pancreas cancer,, SWOG, Huntington Beach, CA, April 29, 2004. Philip A. Philip, M.D. Presentations Page Thirteen 163. Lecture, “Recent Developments in Treating Colorectal Cancer,” the Mayo Clinic, Jacksonville, FL, May 12, 2004. Grand Rounds, “Colorectal Cancers,” South Bend, IN, May 19, 2004. Lecture, “Adjuvant Therapy of Colorectal Cancer,” St. Mary’s Hospital, Livonia, MI, May 26, 2004. Lecture, “ASDCO 2004 Update on Gastrointestinal Cancers,” Dearborn, MI, June 19, 2004. Lecture, “Colorectal Cancer,” Parma Hospital, Parma, OH, June 21, 2004. Lecture, “Therapy: Molecular and Cellular Targets,” Annual Meeting of the Lustgarten Foundation for Pancreatic Cancer Research and the American Association for Cancer Research, San Francisco, CA, June 26, 2004. Lecture, “Recent Advances in the Therapy of Gastric Cancer,” GI Malignancies Management Symposium, Colorado Springs, CO, July 10, 2004. Lecture, “Targeted Therapies in GI Cancers,” Karmanos Cancer Institute Annual Retreat, August 27, 2004. Lecture, “Colorectal Cancer,” Miami Valley Hospital, Dayton, OH, September 3, 2004. Lecture, “Pancreas Cancer,” Karmanos Cancer Center, Population Program’s Annual Retreat, September 10, 2004. Lecture, “Colorectal cancer,” Sparrow Hospital Grand Rounds, Lansing, MI, September 24, 2004. Lecture, “Pancreatic Cancer,” Sylvester Cancer Center, University of Miami, Miami, FL, September 29, 2004. Lecture, “Pancreas Cancer,” Texas A & M University, College Station, Texas, October 4, 2004. Lecture, “Gastric Cancer,” Genesis Medical Center, IL, October 14, 2004. Lecture, “Colorectal Cancer,” MSHO Annual Meeting Symposium, Frankenmuth, MI, October 16, 2004. Grand Rounds, “Colorectal Cancer,” Elyria Hospital, Elyria, OH, November 10, 2004. Lecture, “Targeted Therapies in GI Cancers,” Van Andel Research Institute, Grand Rapids, MI, November 12, 2004. Tumor Board, “Colorectal Cancer; Novel Therapies,” Providence Hospital, Southfield, MI, November 18, 2004. Philip A. Philip, M.D. Presentations Page Fourteen 181. Lecture, “New Therapies for Gastric Cancer,” GI Congress / 8th TCOG Annual Meeting, Taipei, Taiwan, December 4, 2004. Lecture, “Colorectal Cancer,” King Hussein Cancer Center Multidisciplinary Cancer Treatment Symposium, Amman, Jordan, December 5, 2004. Lecture, “Advances in Colorectal Cancer,” St. Joseph Hospital, Ann Arbor, MI, March 8, 2005. Workshop, Lecture and Hospital Rounds, Second Annual Symposium on Colorectal and Prostate Cancers, Hamad Medical Center, Doha, Qatar, April 23 – 27, 2005. Lecture, “The Progress in Targeted Therapies for Pancreatic Cancer,” Arizona Cancer Center, Tucson, AZ, May 27, 2005. Lecture, “GI Malignancies: An Update,” Annual Oncology Review, Karmanos Cancer Institute/ Wayne State University, Dearborn. MI, June 11, 2005. Lecture, “Pancreatic Cancer,” INOVA Alexandria Hospital, Alexandria, VA, June 29, 2005. Lecture and Q & A, “Diagnosis and Treatment of Pancreas Cancer,” Gilda’s Club, Royal Oak, MI, August 10, 2005. Lecture, “Targeting the Signaling Pathways in Pancreas Cancer,” Ireland Cancer Center, University Hospitals, Case Western Reserve University, Cleveland, OH, August 23, 2005. Lecture, “Is Adjuvant Therapy Necessary in Gastric Cancer,” Gastrointestinal Cancer Symposium, Washington University School of Medicine, St. Louis, MO, September 10, 2005. Lecture, “Pancreatic Cancer,” SWOG CRAs Symposium, Dallas, TX, September 23, 2005. Lecture, “Pancreatic Cancer,” Mason City, Iowa, October 24, 2005. Lecture, “Advances in Therapy of Colorectal Cancer,” 1st Annual Symposium on GI Cancer, University of Cincinnati, Cincinnati, OH, November 12, 2005. Debate, “Neoadjuvant Chemotherapy Should be Used in Patients with Resectable Liver Metastases from Colorectal Cancers,” First Annual Roadmap for Colorectal Cancer, American School of Medicine, Salt Lake City, UT, December 17, 2005. Debate, “Adjuvant Chemotherapy Should Not be Used in Patients with Resectable Liver Metastases from Colorectal Cancers,” American School of Medicine, First Annual Roadmap for Colorectal Cancer, Salt Lake City, UT, December 17, 2005. Internal Medicine Grand Rounds, “Colorectal Cancer: Great Steps Forward,” Henry Ford Hospital, Detroit, MI, January 12, 2006. Evening of Experts Series, “Advances in the Therapy of Hepatobiliary Cancers,” UT Southwestern, Dallas, TX, January 19, 2006. Philip A. Philip, M.D. Presentations Page Fifteen 198. Lecture and Case Discussion, “Upper GI Cancers,” 2nd Annual Symposium, Hoag Cancer Center, Huntington Beach, CA, January 26, 2006. Lecture, “Pancreatic Cancer, How can we make a difference,” Department of Internal Medicine, Hematology and Oncology, University of Medicine, Ann Arbor, MI, February 2, 2006. Medicine Grand Rounds, “Colorectal Cancer, Major Steps Forward”, Wayne State University School of Medicine, Detroit, MI, February 15, 2006. Lecture, “Is there a role for neoadjuvant therapy for esophageal cancer?", UCLA, GI Cancer Symposium, Los Angeles, CA, February, 18th, 2006. Lecture, “Colorectal Cancer: Recent Advances”, Bixby Hospital, Bixby, March15th, 2006. Lecture, “Liver Metastases from Colorectal Cancer” Management”, Kalamazoo, MI, April5th, 2006. Lecture, “Management of Liver Metastases”, 8th Annual Palm Beach Cancer Symposium, Shifting Paradigms of Treatment, Palm Beach, Fl, April 8th, 2006. Lecture, Cancer Symposium, Doha, Qatar, April, 2006. Lecture, “Management of Liver Metastases from Colorectal Cancers”, Cook County Hospital, Chicago IL, May12th, 2006. Medical Grad Rounds, “Emerging Trends in the Management of Colorectal Cancer”, St John Hospital and Medical Center, May 23d, 2006, Detroit, MI Tumor Board, “Gastric Cancer”, St Joseph Hospital, Pontiac, May 24th, 2006. Lecture, “Multimodality Therapy of Gastro-Esophageal Cancers”, V International Meeting on Oesophagus and Stomach Surgery, Porto, Portugal, May 29th, 2006. Grand Rounds, “Pancreas Cancer: Are we making progress?”, Karmanos Cancer Institute, Detroit, MI, June 8th, 2006. Lecture, “Gastrointestinal Cancers”, Interpreting Clinical Data: Highlights from ASCO 2006, Dearborn. MI, June 24th, 2006. Medical Grand Rounds, “Pancreatic Cancer”, Roswell Park Cancer Institute, Buffalo, NY, June 30th, 2006. Tumor Board, “Management of Liver Metastases from Colorectal Cancer”, Memorial Hospital, South Bend, IN, July 19th, 2006. Grand Rounds, “Stage II Colon Cancer, Treat or Not to Treat?”, North Michigan Hospital, Petoskey, MI, July 26th, 2006. Tumor Board, “Pancreatic Cancer: Any steps forward?”, St Joseph Mercy Hospital, Ypsilanti, MI, August 2nd, 2006. Philip A. Philip, M.D. Presentations Page Sixteen 216. Keynote Speaker, Targeted Molecular Therapy and Other Novel Approaches in Pancreatic Malignancy”, State of the Art Management of Hepatic and Pancreatic Malignancy, University of Florida and Jupiter Medical Center, Jupiter Beach, November 4, 2006. Lecture, “Gastric and Gastroesophageal Junction Cancers”, State of the Art Treatment of Gastrointestinal Cancers, Karmanos Cancer instate and Wayne State University, Troy, MI, November 11, 2006. Lecture, “Chemotherapy”, Introduction to Oncology and Chemotherapy Course, Bridgehead International, Princeton, New jersey, November 30th, 2006 Grand Rounds, “Pancreas Cancer”, Cancer Center, Henry Ford Hospital, Detroit, MI, December 15th, Lecture, “Gastroesophageal Cancers”, Cancer Center, Thomas Jefferson Hospital, Philadelphia, PA, Lecture, “Multimodality Therapy of Liver Metastases from Colorectal Cancer”, 12th Annual Oncology Symposium, Multimodality Treatment of Colorectal Cancer, 10/28/2006, St Mary’s Hospital, Saginaw, Michigan. Grand Rounds, “Multimodality Management of Liver Metastases from colorectal Cancer”, Sparrow

Source: http://www.hematologyoncology.med.wayne.edu/cv/philip.pdf